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Abstract 
 
 
 
DRUG DELIVERY MICRODEVICE: DESIGN, SIMULATION, AND EXPERIMENTS 
 
By JAE HWAN LEE 
A Dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy in Engineering at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2013 
 
Major Director: Ramana M. Pidaparti, Ph.D. 
Professor, Department of Mechanical Engineering 
 
 
 
 
Ocular diseases such as glaucoma, age-related macular degeneration (AMD), 
diabetic retinopathy, and retinitis pigmentosa require drug management in order to 
prevent blindness and affecting millions of adults in US and worldwide. There is an 
increasing need to develop devices for drug delivery to address ocular diseases. This 
research focused on an implantable ocular drug delivery device design, simulation and 
experiments with design requirements including constant diffusion rate, extended period 
of time operation, the smallest possible volume of device and reservoir. The drug 
delivery device concept uses micro-/nano-channels module embedded between top and 
bottom covers with a drug reservoir. Several microchannel design configurations were 
developed and simulated using commercial finite element software (ANSYS and 
  2 
COMSOL), with a goal to investigate how the microchannel dimensions affect the 
diffusion characteristics. In addition to design simulations, various microchannel 
configurations were fabricated on silicon wafer using photolithography techniques as 
well as 3D printing. Also, the top and bottom covers of the device were fabricated from 
PDMS through replica molding techniques. These fabricated microchannel design 
configurations along with top and bottom covers were all integrated into the device. Both 
single straight microchannels (nine different sizes of width and depth) as well as four 
micro-channel configurations were tested using citric acid (pH changes) and Brimonidine 
drug (concentration changes using the Ultra-Violet Visible Spectrophotometer) for their 
diffusion characteristics. Experiments were conducted to obtain the diffusion rates 
through various single micro-channels as well as micro-channel configurations using the 
change in pH neutral solution to verify the functionality and normalized diffusion rate of 
microchannels and configurations. The results of experimental data of diffusion rate were 
compared with those obtained from simulations, and a good agreement was found. The 
results showed the diffusion rate and the optimum size of microchannel in conjunction 
with the required drug release time. The results obtained also indicate that even though 
specific diffusion rates can be obtained but delivering the drug with constant amount 
needs a mechanism at the device outlet with some control mechanism. For future studies, 
this result may be used as a baseline for developing a microfabricated device that allows 
for accurate drug diffusion in many drug delivery applications. 
 
 
  3 
CHAPTER 1 Introduction 
1.1 Motivation 
The human eye has a very exclusive and complicated function for visualization 
while magnifying and transferring its image data through the optic nerve in cooperation 
with various compartments of particularly special structures.  As shown in Figure 1.1, 
normal human eye can be divided into two main groups as the anterior segment includes 
the cornea, lens, iris, and ciliary body. And the posterior body contains the sclera, choroid, 
optic nerve, retina, macula, and vitreous body. There are many eye diseases which can 
affect to eye and led to vision loss. These diseases are correlated to the function of 
relevant anatomy and physiology of the eye. Typically, common eye disorder symptoms 
can be represented as redness (blood shot), itching, tearing, swelling, burning, trauma, 
pain or discomfort, blur (decrease in vision), and spots. The eye diseases in terms of 
treatments can be described as Cytomegalovirus Retinitis (CMV, is mostly affected to 
people with poor immune systems), Conjunctivitis (pink eye), Diabetic Retinopathy, Eye 
Herpes, Glaucoma, Age-related Macular Degeneration (AMD), Ocular Hypertension, 
Stargardt's Disease (STGD), and Retinitis Pigmentosa [1].  
Most of ocular disease is treated by the topical application of solutions to the 
surface of the eye as drops because of relatively less expensive and of easy to use by 
patients. However, it has been estimated that typically less than 5% (or only 1 – 10%) of 
a topically applied drug absorbs the cornea and reaches intraocular tissues insufficiently 
[2, 3, 4, 5]. The relatively small proportion of a topically applied drug dose reaches at the 
back of the eye where the posterior segment as well as ocular tissues, and macula. 
  4 
 
 
Figure 1. 1 Anatomy of the human eye, figure courtesy of NIH Medical Arts. 
 
The conventional topical drop also can cause severe side effects of visual 
interferences in accordance with frequent dosing and amount of dosage. The drug using a 
needle with syringe can be injected, but it barely provides the right amount of dose and 
over doses may cause more severe problems such as swelling, fatigue, and damage 
photoreceptor molecules. Furthermore, most drugs run out in a month and repeated 
injections become necessary [2]. Developing an implantable drug delivery device will 
help reduce the costs and risks associated with frequent injections and facilitate 
delivering the drug in a controlled manner and in the required amounts and improve 
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therapeutic efficacy and safety of drugs. An accurately controlled release with 
biocompatible and especially refillable drug delivery device for a long time operation is 
necessary to improve for sufficient drug transport with high efficiency at the right time 
and right place and to provide better therapeutic performance of drug while avoiding an 
interruption of vision.  
 
 
1.2 Approaches 
Ocular diseases, such as, glaucoma, age-related macular degeneration (AMD), 
diabetic retinopathy, and retinitis pigmentosa require drug management in order to 
prevent blindness [6]. These incurable diseases require lifelong treatment through orally 
administered medications, intraocular injections, and biodegradable implants. Drug 
delivery to ocular tissue is very difficult due to area and size limitations in the eye. There 
are currently at least three major categories of ocular drug delivery systems as discussed 
in [7]: biodegradable or nonbiodegradable, atypical implantable pump systems, and 
implantable pump systems. Implantable pump systems dispense drugs from an internal 
reservoir and have the advantage of providing control over drug delivery rate and volume. 
Several types of implantable pumps, such as, infusion pumps, osmotic pumps, and 
peristaltic pumps have been developed and used successfully for applications, such as, 
insulin delivery but have been found to be unsuitable for ocular drug delivery due to 
space limitations. Typical implantable pump systems (hydrogel systems infused with 
drug swell via intake of biological fluids for example) minimize the drug volume 
  6 
required for treatment and provide targeted delivery at a constant rate. However surgical 
procedures are required to implant and replace these devices, which may in turn 
contribute to additional side effects. Vitrasert and Retisert distributed by Bausch and 
Lomb are commercially available examples of nonbiodegradable systems. In these 
systems, the drug is released as a polymer matrix infused with drug dissolves or the drug 
is distributed from a nonbiodegradable reservoir. The disadvantages with these systems 
include in vivo polymer degradation (and the drug cannot be refilled) and the fact that 
drug delivery is dependent upon a limited volume available within the polymer. 
Several Micro Electro-Mechanical System (MEMS) devices, such as 
microreservoirs and micropumps have been fabricated to address the spatial constraints 
posed by ocular drug delivery [7, 6]. Microreservoirs offer maximum control of drug 
delivery but cannot be refilled or reused, thereby ruling out suitability for treating chronic 
eye conditions. Peristaltic micropumps provide targeted drug delivery through active 
pumping but require considerable space to achieve a desired volume of flow per minute. 
To overcome these limitations, Lo et al. [8] recently developed a first generation 
prototype polymer MEMS delivery device with a refillable drug reservoir for treating 
ocular diseases. In addition to the refillable drug reservoir, the device consists of a 
transcleral cannula, check valve, and suture tabs. The device requires surgical 
implantation underneath the conjunctiva and the specified dose of medication is 
dispensed from the device when the reservoir is mechanically activated by the patient’s 
finger. This device has several advantages when compared to existing systems including 
the following: the device is refillable, requires only a single surgical intervention, and is 
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suitable for treating chronic ocular conditions; it is compact and fits within the 
dimensions imposed by the ocular orbit (<2mm thick). However, the device requires 
patient’s intervention in dispersion of the drug. 
In order to cater to multiple scenarios in terms of amount of drug delivery and 
constraints, alternate MEMS devices might be of interest for treating ocular diseases. 
Nano-/microchannel-based drug delivery technologies represent an unprecedented 
opportunity to realize radically new devices that would exploit the novel features of the 
nanochannels, in which chip contains that drug reservoir with dose, provide unique 
performance in terms of diffusion and kinetics over existing technologies for drug 
delivery applications [9].  
Age-related Macular Degeneration (AMD) is a common eye condition among 
people age 50 and older, and gradually destroys the macula. ADM disease causes the 
vision loss that makes it difficult to recognize faces, drive a car, read, print, or do close 
work. AMD does not advance vision loss in a short period of time. Therefore the constant 
long term drug application is desirable for patients suffering with chronic conditions as 
well as AMD. Many variables control availability that is dependent on composition.  For  
drugs  or  compositions of solution,  chemical  reactivity,  total  drug  concentration  and  
kinetics  of  transport mechanism engage  a significant  part  in  controlling  total  mass 
diffusion  rate/ flux.  The  chemical and physical  properties  of  the  drug itself  are  
mostly influence to final  drug  diffusion  and  availability  in  ocular  tissue  [10]. The 
Fick’s second law of diffusion model can predict the diffusion time of the local tissue 
concentration in the eye following a variety of microchannel geometries for ocular 
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implantable delivery. The diffusion coefficient of drugs may vary based on the chemical 
properties and internal structure as well as the molecular weight of the drug. 
In this study, the design, simulations, fabrications, experiments, and evaluation 
are conducted to ensure that the diffusion occurs through a micro-scale channel and the 
effect of microchannel size. A novel approach to the fabrication of a diffusion-type 
microdevice and its PDMS, the various geometries using the microfabrication technology 
is conducted. The microchannel can be operated as the dynamic filter and controlled 
easily by the dimension of channel without any additional features for the fabrication of 
the microvalves. 
 
1.3 Background and Significance 
1.3.1 Impacts of AMD on Vision loss 
New drugs for treating eye diseases have been developing over the past decade 
and are very unique for each eye diseases such as glaucoma, cataracts, and age-related 
macular degeneration (AMD). It is estimated that 1.6 million adults in the US over the 
age of 50 and above suffer from age-related macular degeneration and about 200,000 
cases are diagnosed annually. Worldwide, about 500,000 cases are diagnosed annually 
[7]. AMD disease is the most cause of severe central vision loss in older people. It is a 
very critical disease that may advance rapidly and destroy central vision from Figure 1.2, 
it is shown that central vision is blurred after retina or macula damages with AMD 
diagnosed eye.  
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Drugs currently utilized for AMD are delivered via repeated intravitreal 
injections of the drug into the eye. Risks of repeated intravitreal injections can include 
intraocular infections (endophthalmitis), intraocular hemorrhage, and retinal detachment. 
Also, reducing the frequency of dosing will clearly benefit the patient by reducing the 
need for risky intravitreal injections and improving the pharmacokinetics of the drug in 
the eye. Eye disease in the posterior segment includes two different forms of AMD such 
as Dry and Wet. Approximately 90% of patients with AMD have the Dry form 
shown in small yellow and white deposits form made of proteins and waste 
products. Wet AMD is caused by abnormal blood vessels grow out of the retina 
followed by rapid vision loss. However these AMD diseases limit drug delivery in the 
retina region driven by eye drops [14, 15].  The treatment of vitreous body segment 
disease still has a significant limitation and difficulty in delivering effective doses of 
drugs to targeted area in the vitreous body of the eye [16, 17, 18].  
 
a) b) 
c) 
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Figure 1. 2 Comparisons between normal and AMD diagnosed human eye; a) left, CT 
scan of normal and b) AMD diagnosed, c) people clearly perceive an object with normal 
vision, d) AMD patient has a difficulty to see center area of vision. A computed 
tomography (CT) scan captured from the www.FightBlindness.org, "Treatment & 
Therapy for AMD." 
 
1.3.2 Drug Administration for Human Eye Diseases 
Many ophthalmic drug delivery systems were developed and available to 
overcome specific problems. In the past decades, significant advances have been made to 
develop the drug delivery devices for the eye disease and to maintain effective drug doses 
methods such as in situ gel (hydrogels), ocular insert, nano/micro particle, nano/micro 
suspension and micro-emulsion has been developed [2, 19-24].  
It can be seen in Figure 1.3 a), b) that high peak levels or less effective drug levels 
of dug amount can cause severe side effects. The controlled release and implant release 
concept (Figure 1.3 c), d)) are appropriate for drugs with a longer period of time to 
maintain therapeutic plasma concentrations. The administration intervals can be increased 
in accordance with elimination rate of drugs in the eye. Moreover, high plasma peak 
levels which can cause side effects can be reduced. 
d) 
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Figure 1. 3 Four different types of drug release; a) frequently dose every 1 or 2 weeks, b) 
rarely dose every 10 or 20 months, c) one time dose with controlled release, d) implant 
dose with diffusion release.  
 
It is shown in Figure 1.4 that nonbiodegradable and biodegradable drug delivery 
methods in the eye region in accordance with the function of time and derivatives of fluid 
sources (drugs) are discussed [25]. The Vitrasert implant contains a ganciclovir tablet 
coated with polyvinylalcohol (PVA) and ethylene vinyl acetate (EVA) polymers. 
Research is continuing on biodegradable implants to determine their clinical application. 
Right side view shows biodegradable release systems include Lacrisert®, scleral plug, 
Episcleral implant, and Injectable rod. Figure obtained and modified from Tsutomu et al 
[25].  Left side view shows nonbiodegradable release systems include Prosert® (IOL 
Tech), Lacrisert®(hydroxypropyl cellulose-ocular system; Merck), Vitrasert®(sterile 
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intravitreal implant with ganciclovir; Bausch &Lomb), and Retisert® (fluocinolone-
intravitreal implant;Bausch & Lomb) [25]. 
 
 
Figure 1. 4 Schematics of ocular controlled release systems; a left-side view shows 
nonbiodegradable release systems (reservoir type) include Ocusert®, Prosert®, Vitrasert®, 
Retisert®, Intrascleral disc, and Macular implant. A right side view shows biodegradable 
release systems include Lacrisert®, scleral plug, Episcleral implant, and Injectable rod. 
Figure obtained and modified from Tsutomu et al [25].   
1.3.3 Features of Vitreous Body 
The vitreous body is supported by a network of collagen and contains a 
transparent gel between the lens and the retina. It is about 80% of the volume of the 
eyeball and delivers an object image to the optic nerve. About 2% of salts, sugars and 
Subretinal and epiretinal 
 implant 
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collagen fibers make up the vitreous body. 98 % of the body is hyaluronic acid that a 
substance is an excellent eye lubricant and a stronger bonder with water. Viscosity of 
vitreous is about 2 to 4 times higher than pure water. There are no blood vessels. Vitreous 
keeps contact with the retina and helps it keep immobile by pressing against the choroid. 
Vitreous contents are not continually replenished like those of aqueous humor. The 
contents are static, meaning that if anything gets into it, it will remain there unless 
surgically removed [26]. 
 
1.3.4 Types of Controlled Drug Release System 
Typical oral administrations are essentially inefficient and often require repeated 
dosing to maintain the amount of drug within the therapeutic range. It sometimes requires 
increased dosages to ensure release of a sufficient amount of drug to the target site. 
Moreover, specific methods of injection administration can be painful based on the cyclic 
dose and the amount of injection. The controlled drug release system of therapeutics 
offers significant advantages over conventional delivery methods of drug administration. 
Controlled release devices can provide drugs at a steady-state, and constant rate for over 
long periods of time while minimizing deviations from the therapeutic range. Such 
advantages of controlled-release devices increase a patient convenience and reduce a 
waste of drug. 
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1.3.4.1 Dissolution controlled systems  
There are two main types of dissolution controlled system; the encapsulation and 
matrix dissolution controlled system. Micro-encapsulation of drug particles is a common 
method that is used to develop reservoir type of devices including drug cores. Typical drug 
particles are coated by microencapsulation form which can be added into the drug device.  
The drug encapsulation is influenced by certain characteristics of the particle such as 
properties of drugs, biodegradable polymer, and organic solvent; and operating conditions 
including drug concentration, diffusion coefficient, solubility, temperature, pressure, and the 
level of mixing. Therefore, optimization of these conditions is very important to produce the 
appropriate particle size with narrow distribution [27, 28, 29].  
Matrix dissolution controlled system is related to the fraction of drug loaded into 
the matrix that will eventually be released. The volume fraction dissolubility is 
importance of matrix dissolution controlled system as a release rate of drug from 
polymeric matrices. These applications have enabled new insights about the design and 
characterization of dosage forms and drug release properties. In this system the drugs in 
surface layer exposed to the solution are dissolved and then diffused out of the 
matrix.  This process continues within the boundary between solution and the solid drug 
moving controlled. The rate of dissolution of drug particles within the matrix must be 
faster that the diffusion rate of dissolved drug leaving matrix. Some researchers were 
studied basic percolation concepts to modify and evaluate the pseudo-steady models in 
pore diffusion problems as matrix release systems [30, 31, 32].  
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1.3.4.2 Diffusion (reservoir) controlled systems  
The drug release rate of diffusion controlled systems is dependent on its diffusion 
coefficient through membrane barrier. A core of the drug is surrounded by polymeric 
membrane. The nature of this membrane determines the release rate of drug from system. 
According to the Fick’s law, the amount of drug passing across a unit area in the process 
of diffusion is proportional to the concentration difference across the area [33]. 
 
1.3.4.3 Water penetration controlled systems  
The release rate in water penetration controlled delivery systems is determined by the 
penetration of water into the system. Two general types of these systems include, swelling 
controlled release systems and osmotically controlled delivery systems. Swelling controlled 
release systems are initially dry, when first placed into the body. The system will absorb 
water or other biological fluids and swells. Swelling increases the aqueous solvent content 
within the formulation as well as the polymer mesh size, enabling the drug to diffuse through 
the swollen network into the external environment. However most of the materials used in 
swelling controlled release systems will swell without dissolving when exposed to water or 
other biological fluids [34]. The drug release from the osmotic system is largely 
independent of the pH reaction. The membrane in the osmotic system is selectively a 
water permeable membrane and an effective isolation of dissolution process of drug core 
from the surrounding environment. The cellulose polymer acetate membrane is 
commonly used because of its high water permeability characteristics and it can be 
adjusted for various degrees of acetylation of the polymer. The permeability of this 
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membrane can be increased further by adding plasticizer to the polymer. This increases 
the water diffusion coefficient or hydrophilic flux enhancer which increases the water 
sorption of the membrane [35, 36, 37]. 
 
1.3.4.4 Hydrogels  
Hydrogels are a special type of mesh like hydrophilic polymer that has the ability 
to absorb large amounts of fluid. It can absorb typically 60-90% fluid at complete swell and 
only 10-40% polymer remains as its fibroin structure. In case of polymer hydrogel, initially 
the diffusion coefficient of agent in the dehydrated hydrogel is very low. However once the 
gel absorbs water, a significant increase of the diffusion coefficient is occurred. The degree 
of cross-linking, linear molecules bonded to each other, is partly determined by the 
concentration of the polymer. The polymer will be a weak mesh at low concentration. 
Cross-linking will become the tighter when concentration is increased. The most well 
known hydrogel is gelatin which is a processed version of collagen that accounts for one 
thirds of the protein in the body [38].  Wang et al [38] have studied the nonlinear 
mechanical coupling between pH-responsive polymers and ion-exchange reactions for 
periodically releasing enclosed particles without external resources. 
 
1.3.5 Refillable Drug Release System 
 
In a recent study, Ellis Meng et al (2012) [39] have investigated the implantable delivery 
device as a micro-electromechanical system (MEMS) for the treatment of chronic and 
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refractory ocular diseases [8, 40, 41]. It can be seen in Figure 1.5 that their device can be 
refilled with drug solution to provide long-term drug therapy while avoiding repeated 
surgeries. The first generation of MEMS is a manually controlled system limited by 
variations in the drug-release duration and force applied for depressing of the reservoir. 
To resolve this problem, the next generation device consists of an electrolysis chamber 
with electrolysis actuation to precise delivery of the desired dosage volume, a drug 
reservoir with refill port, battery and electronics. Biocompatible and flexible parylene is 
used to construct the MEMS. Battery and wireless inductive power transfer can be used 
to drive electrolysis.  
 
Figure 1. 5 Illustration of the implantable ocular drug delivery device concept with a 
refillable port, reprinted from Lo, R. et al, 2009 [8]   
Electrolysis is a low power process in which the phase change of water to 
hydrogen and oxygen gas is induced electrochemically. The change generates pressure in 
the reservoir forcing the drug through the cannula [8]. The reservoir is implanted in the 
subconjunctival space, and the flexible cannula is inserted through an incision into the 
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anterior or posterior segment. Gonzalez-Soto et al [42] have demonstrated that a slower 
prolonged infusion of the same volume and concentration of intravitreal ranibizumab is 
equivalent to a bolus intravitreal injection of ranibizumab in a human VEGF-induced 
retinal hyperpermeability model in rabbits. 
In 2009, Replenish Inc. have started clinical trials for F.D.A. approval for a 
refillable and programmable pump that would be implanted into the eye to feed medicine 
for glaucoma or AMD. They focused on the controlled release, which would last for more 
than 5 years before replacement is required. This is much longer than current treatments 
[43]. 
Genentech developed a refillable port drug delivery system (PDS) that was 
designed to release ranibizumab over a period of months in collaboration with ForSight 
Vision 4 Inc. [44]. To develop the PDS, a safety and preliminary efficacy study have 
been conducted in patients with neovascular AMD [45]. 
 
1.3.6 Computational Models for Investigating Ocular Drug Delivery 
A  simplified  cylindrical  vitreous  body  model  had  been developed  b y  
Ohtori et al [46] for  the  pharmacokinetic  model  of  intravitreal drug injection. Their 
cylindrical vitreous body model had well presented the elimination profile of ocular 
drugs in the rabbit eye. The model parameters, such as the diffusion coefficient, the 
partition coefficient, the metabolic reaction rate constant were studied. The vitreous 
concentration is basically very low and decreases extremely close the posterior segment 
based on the boundary barrier and elimination factors, which are related to complicate 
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distribution and consumption. The retina membrane could be considered as an 
elimination component of drug molecules while analyzing a cylindrical vitreous model. 
They also investigated the parameters of binding in the vitreous body from the in-vitro 
experiment [46, 47].  
Drug diffusion in the vitreous body of the three dimensional eye model have 
been performed by Friedrich  et  al [48] and Park et al [49]. The combined effects of 
diffusivities were simulated to evaluate the influence of vitreous outflow on drug 
distribution while keeping the retinal permeability constant. The effect of the high (Dh; 
1x105 cm2/s) and low (Dl; 1x107 cm2/s) diffusivity of drug in vitreous humor was 
investigated while comparing an intravitreal injection and implant using a finite 
element model.  They suggested that the implantable drug delivery device could be 
advantageous to reduce the risks of instantaneous high concentration from an injection 
and to sustain the releasing of the drug for a long period of time. 
 
1.3.7 Drugs and Diffusion Coefficient for AMD   
Several models have been used to study the drug delivery mechanisms [50, 51]. 
Recently, a review of barriers to posterior eye drug delivery and the challenges and 
opportunities were discussed by Thrimawithana et al. [52]. Table 1 summarizes various 
drugs, their diffusion coefficients, the average dosage, and the frequency to treat AMD 
diseases. Fick’s second law of diffusion can be used to describe the transport of drug into 
the eye using microchannels. As the drug delivery device is implanted in the vitreous 
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body of the eye, usually the diffusion rate depends on the local concentration between the 
drug reservoir and the vitreous humor. 
Table 1 Diffusion coefficient of drugs for the AMD disease 
Drug Drug name (type) 
Diffusion 
Coefficient 
(cm2/s) 
Average 
Dosage 
(nl/min) 
Injection 
amount/periods References 
Anti-angiogenic  
Macugen 
(Pegaptanib sodium) 
 
3 x 10-7 0.2083 3mg/10days Swanson S. D. (2006) [53] 
Lucentis  
(Ranibizumab) 
 
2.08 x 10-7 0.0124 0.5mg/month Molokhia et al. 
(2010)[54] Intravitreal Avastin 
(Bevacizumab) 
 
1.25 x 10-7 0.0289 1.25mg/month 
Synthetic 
corticosteroid 
Fluocinolone 
Acetonide, 2.3 x 10
-7 0.0744 15mg/20weeks 
Li T.et al. (1997) 
Jaffe G. J. (2000)
[55, 56] 
 
1.3.8 Drug Therapy for Ocular Glaucoma Disease 
Treatment in glaucoma disease is mainly to lower intraocular pressure (IOP) in 
order to decrease the risk of severe progress and vision loss. The brimonidine is one of 
the appropriate drugs to effectively lower IOP [82, 83]. Due to the similar diffusion 
boundary conditions with AMD, the Brimonidine is applied to characterize the diffusion 
rate and is well tolerated.  In this study, the Brimonidine for the treatment of glaucoma is 
investigated for the possible drug for diffusion. 
 
1.4 Specific Objectives 
The overall goal of this research is to develop the optimized drug delivery system 
while studying the role played by various geometrical components of fluidic 
microchannels. And then develop the microchannel fluid model to study velocity and 
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pressure distributions in the eye. After understanding fluid characteristics of the 
microchannel, diffusion with hydrophilic surface for drug delivery application is 
developed. The various microchannels in a drug delivery device are investigated to 
achieve a constant diffusion rate for its application in the AMD disease. 
This study focuses on the design, simulation, and development of an implantable 
ocular drug delivery device. A novel design concept consisting of micro/nanochannels 
embedded between top and bottom covers with a drug reservoir made from PDMS 
material was developed. Several simulations were carried out with different microchannel 
configurations in order to see the feasibility for ocular drug delivery applications. Finally, 
the drug release time from the drug delivery device in accordance with a size of 
microchannel and diffusion coefficient can be predicted from the diffusion rate profile 
by the present model.   
 The procedure consists of four main steps: 
Step 1: Design 
In step 1, simple idealized microchannels with five different sizes of width and 
depth are developed. The straight microchannel A (100µm - 1000µm) is designed 10 mm 
long that can be inserted into the device and tested with same amount of the vitreous 
liquid of eye.   The straight microchannel B (200µm - 1000µm) is designed 20mm long 
that is considered to obtain the diffusion rate and particle image velocimetry. The eyeball 
with device implants is developed based on the possible application and surgery easiness. 
The alignment of the device is optimized when the results of simulation are obtained. The 
four different microchannel configurations are developed to be performed as a filter for 
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drugs and to avoid the back flow from the vitreous segment of eye. The generic drug 
delivery system based on PDMS (Polydimethylsiloxane) is designed. 
Step 2: Simulation 
In order to understand the design characteristics of the channel, a micro-device for 
drug/fluidic transport mimicking the coarse-grained representation of the microchannel 
geometry through computational fluid dynamic analysis and optimization is developed. 
Specifically, the role of the channel configurations in active fluidic transport and passive 
transport is investigated. Results of flow rate, pressure and velocity profiles obtained 
from the models indicate that the microchannel plays a major role in transport through 
this entire device. The results of this investigation show that fluidic transport and flow 
passages are important factors in designing microchannel based devices for drug delivery. 
The present approach can be extended along with multi-scale microchannels to 
further understand the diffusion characteristics of microchannel geometry.  
In practical applications of microchannel flow, we assume that the majority of micro-
system flows are laminar due to the high pressure drop in microchannels caused by 
relatively small channel dimensions. A combination of dimensionless Reynolds numbers 
indicates the importance of inertial to viscous forces, energies and time scales present at 
the microscale [11, 12, 13]. Within a certain low range of Reynolds numbers (Re< 1), 
laminar incompressible viscous flow may dominate the flow field over the entire 
microchannel length. The design concept of microchannels within the drug delivery 
device has been investigated to develop constant diffusion rate and low pressure 
operations if it is applicable.  
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Using ANSYS thermal transient analysis, the several design concepts for drug delivery 
channel within a device are investigated and simulated to obtain an optimum and constant 
diffusion rate for the drug concentration. ANSYS Fluent and Post-CFD is performed to 
optimize diffusion flow of a micro fluidic device in which is implanted into the barrier of 
vitreous body of the human eye.  COMSOL Multiphysics® is performed to compare 
diffusion rate of the Brimonidine (drug therapy for an ocular glaucoma disease) with 
experiments.   
 
Step 3: Fabrication  
In the following, five straight microchannels are fabricated on the Lexan® glass 
to obtain diffusion performance.  And then the fabrication of PDMS and microchips, 
which allows inexpensive, durable, and biocompatible devices, is processed. 
Microchannels are fabricated by micro-electronic technologies onto the substrate 
followed by bonding a PDMS of reservoir. A bonding process is conducted by oxygen 
plasma treatment. PDMS and Si substrate have typically hydrophobic surface that affects 
diffusion coefficient. Thus the surface treatment using optimized oxygen plasma process 
is conducted to form a silanol group. A solvent assisted system is considered to soften 
less than 50 nm of the surface of microchannel during bonding while maintaining 
microchannel integrity.  
 
Step 4: Test 
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After completion of prototype samples, the change in pH neutral solution is 
measured to verify the functionality and diffusivity of the single microchannels and entire 
device including various microchannel configurations. Both design simulations and 
experiments are carried out to evaluate the drug delivery device for its functionality and 
diffusion characteristics. The evaluation test in comparison with the analytical solution is 
completed using micro-PIV (particle image velocimetry). The micro particle image 
velocimetry (µPIV), an optical method, is performed to visualize and analyze the flow 
rate and flow characteristics in the microfluidic channels using MATLAB PIVlab 1.31, 
which is one of the latest user defined computational code. The diffusion rate of 
polystyrene with standard 3.0µm diameter (National Institute of Standards and 
Technology (NIST), traceable particle size standard) is measured as a similar to drug 
concentration. 
 
 
1.5 Organization of the Dissertation 
 
The rest of the dissertation is structured as the followings. Chapter 2 discusses the 
details used to develop the model design. The concepts of the drug delivery model are 
also provided. Chapter 3 describes the procedures and the boundary conditions of the 
model to perform the simulation of single microchannels and the entire device model. 
The results from the microchannel and entire device model are also discussed. Chapter 4 
provides all details of the fabrication of PDMS and Microchannels include curing process, 
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Si substrate oxidation, KOH etching and oxygen plasma. This chapter illustrates the 
experiment techniques that are used to conduct the diffusion test using present models. 
Finally, scientific contributions of the research and recommendations for other 
researchers are presented in the Chapter 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 Model Designs for Device and Experiment 
2.1  Introduction 
Controlled release drug delivery is a challenging way to treat illnesses. The term 
controlled release refers to the ability of a drug delivery system to release a drug over an 
extended period of time at a controlled rate. Over the last 20 years, it has become more 
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popular for treatments of chronic diseases. It generally involves implanting a 
biocompatible polymer directly into the diagnosed region of the body that is aﬀected by a 
disease. Since the polymer is implanted directly into the tissues affected by disease, the 
side eﬀects are often small compared to conventional drug delivery (i.e. eye drop or 
injection). A controlled release system can increase accuracy of the dosing to overcome 
the side effects of pulsed dosing produced by conventional systems. It is possible to 
provide comfort, better compliance to the patient and to improve the therapeutic 
performance of drug. Diffusion represents a highly efficient means for the generation of 
concentration gradients for a long time operation. Drug concentration in DI water can be 
generated with relative concentration of the vitreous cavity along the gradients. Therefore, 
microfluidic channels are used. As a first step, diffusion of drug in single straight 
microfluidic channels is investigated. 
 
2.2 Theoritical Background 
The movement of drug across a microchannel in a manner driven solely by the 
concentration gradient is a passive diffusion. In passive diffusion, drug moves from a 
region of greater concentration to a region of lesser concentration. When the dose of a 
compound that is released by passive diffusion is increased, the percent of the dose that is 
eliminated remains the same. In contrast, there is a decrease in the percent of the dose 
that is eliminated when increasing the dose of a drug released by a concentration process. 
We can illustrate the power of this approach by deriving Fick’s law of diffusion in one 
dimensional model [57]. 
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2.2.1 Diffusion by Fick’s Law 
The principle mechanics in physics depict that a particle in a mechanical or 
gravitational field always moves from a point of high potential energy to one of lower 
potential energy. Another way of stating this fact is that there is a force on the particle 
given by 
ܨ௥ ൌ െߘܸሺݎሻ          (1) 
or in one dimension 
ܨ௫ ൌ െௗ௏ௗ௫   ݋ݎ  െ 
డ௏
డ௫         (2) 
However, in contrast to motion in free space, motion of molecules in liquid involves 
frictional forces. A particle moving in such a medium must cause displacement and 
separation of these interacting molecules. Force is required and the net result is an 
expenditure of energy. When the path of a particle involves the separation of two or more 
molecules, work is done by the particle on these two or more molecules. This work or 
energy expenditure is not recovered by the particle when the two or more molecules 
again return to their average intermolecular distances. Instead, this work of separation is 
dissipated as heat characteristic of irreversible processes. In fact, the rate of energy 
dissipation by the moving particle is proportional to its velocity. This rate of energy 
dissipation is known as a frictional force. This frictional force is not only a property of 
the particular medium through which the particle is moving, but is also dependent on the 
particle size and shape. The larger the size, the greater the resistance encountered. The 
inherent property of the medium which determines the friction force is called viscosity η, 
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and is related, in part, to the degree of molecular interaction and molecular size and shape. 
Thus, the diffusion coefficient also depends on size and shape of molecule, interaction 
with solvent and viscosity of solvent. The diffusion coefficient equation is given as 
ܦ ൌ ௞್்௙           (3) 
Where f  is a friction coefficient, it can be expressed by 
݂ ൌ 6 ߨߟݎ           (4) 
By substituting equation (4) into equation (3), we get  
ܦ ൌ   ௞್்଺గఎ௥              (5) 
in which kb is the Boltzmann-constant, T the absolute temperature, η the viscosity 
of the medium, and r the radius of a sphere diffusing in the liquid, the diameter of a 
sphere diffusing in water. 
 
2.2.2 New Fick’s Law with Navier-Stokes Equation 
 
Mass transfer by viscous flow is much faster than that by diffusion under all the 
simple channel flows. If the simple channel flows are due to biased random motions of 
atoms, the same driving force such as a pressure gradient should produce similar rates. 
However it is proven to differ by many orders of velocity and pressure magnitude. 
Whether these are entirely different processes or same processes remains a question. In a 
liquid, all atoms are moving in random motions which produce both diffusion and 
viscous flow when influenced by a driving force. It is difficult to see how they can 
proceed by exclusive singular motion mechanisms. The solid states in a liquid are 
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different because self-diffusion takes place by atom-vacancy exchanges and such 
diffusion may produce shape changes or particle flow of solids. If all the contiguous 
atoms are moving in one direction, the central atom can be moved in the same direction 
without any effort of its own. In other words, it moves with its adjacent without any 
chemical potential gradient at all in the moving direction. In addition, if an atom has a 
chemical potential gradient, it moves forward to adjacent atoms in accordance with the 
novel idea of Fick’s first law [58]. 
 
Once  we  set  the  velocity  ux of a molecule in the x direction in a flow field, it can be 
relative to some fixed frame. Then the velocity of the molecule ahead of it is 
 ݑ௫ ൅ ܽ డ௨ೣడ௫ ൅
௔మ
ଶ
డమ௨ೣ
డ௫మ     (6) 
 
In which a is the distance at which the first peak of the radial distribution function 
appears. Usually the first nearest neighbor is located there. Similarly the velocity of the 
nearest neighbor at the back of it is   
ݑ௫ െ ܽ డ௨ೣడ௫ ൅
௔మ
ଶ
డమ௨ೣ
డ௫మ         (7) 
Since the velocity difference between front and back neighbors such as  డఓೣడ௫  , - ܽ 
డఓೣ
డ௫  ,  
the average velocity of the two neighbors is expressed by 
ݑ௫ ൅ ௔
మ
ଶ
డమ௨ೣ
డ௫మ          (8) 
Hence the velocity of this atom relative to its neighbors in the x direction is 
ݑ௫ െ ሺݑ௫ ൅ ௔
మ
ଶ
డమ௨ೣ
డ௫మ ሻ        (9) 
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If there is a driving force for diffusion such as a gradient of chemical potentialபµப୶, this 
atom should have a velocity relative to its neighbors based on Fick’s law:  
        ௔
మ
ଶ
డమ௨ೣ
డ௫మ ൌ
஽
ோ்
డఓ
డ௫         (10)  
For all three components of 3D coordinates of velocity, it can be expressed  
        ׏ଶݑ௫ ൌ ଺஽௔మோ் ׏ߤ         (11) 
Since the velocity u is the flux J divided by the concentration c, this equation can 
also be written as 
ݑ௫ ൌ ௃௖          (12) 
׏ଶܬ ൌ ଺௖஽௔మோ் ׏ߤ         (13) 
where c is number of moles per unit volume or the reciprocal of molar volume. This 
is the new Fick’s law for self diffusion in liquids [58].  
 
 
2.2.3 Mass Transfer Coefficient in Molecular Diffusion 
Mass transfer through diffusion occurs whenever fluid has different concentration 
of the physical properties so that some mass is diffused from one place through another.  
This research is not focused on mass transported by this volume fluid motion, but rather 
on the transport of one chemical species within a mixture of chemical species that occurs 
as a direct result of a concentration gradient and is independent of a pressure gradient. 
Many of the solution techniques for conduction heat transfer can be applied directly to 
mass transfer and diffusion problems. Mass diffusion refers to the diffusive transport of a 
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species due to concentration gradients in a mixture.  Mass transport by diffusion is 
analogous to conduction, which is the diffusive transport of energy due to temperature 
gradients. Therefore, the molecular description of diffusion is similar to the molecular 
description of conduction. 
The flux of molecules of all species that are passing through a horizontal plane at 
position x is proportional to the molar density of the mixture N and the mean velocity of 
the molecules vm at that location. These molecules practice their last molecular interaction 
at x–Lm, where Lm is the average distance between molecular interactions. 
Therefore, the number of these molecules that are of species i is proportional to the mole 
fraction of species i at position x-Lm.  The molar flux of species i passing through a plane 
located at position x in the positive x-direction due to diffusion ሺ߲ ௜ܰ,௫" ሻ  is given 
approximately by  
߲ ௜ܰ,௫" ൎ ܰݒ௠ݕ௜,௫ି௅೘         (14) 
The length between molecular interactions is much smaller than the length scale that 
characterizes the problem, Equation14 can be written in terms of the gradient in the mole 
fraction of species i  
߲ ௜ܰ" ൎ െ2ܰݒ௠ܮ௠ డ௬೔డ௫          (15) 
Equation 15 provides the motivation for Fick's law, which states that diffusive mass 
transfer  is proportional to the gradient in the mole fraction of species i.  The diffusion 
coefficient for species i through the mixture (D i,m) can be expressed by 
߲ ௜ܰ" ൌ െܰܦ௜,௠ డ௬೔డ௫ ൌ െܦ௜,௠
డ௡೔
డ௫        (16) 
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On a mass basis, the gradient in the mass fraction or mass concentration of species is 
connected to the diffusive mass flux of species i ሺ߲݉௜"ሻ, Fick's law can also be written by 
߲݉௜" ൌ െߩܦ௜,௠ డ௠௙೔డ௫ ൌ െܦ௜,௠
డ௖೔
డ௫        (17) 
Equations 16 and 17 are statements of Fick's law of diffusion and define the diffusion 
coefficient for species i in the mixture in the same way that the empirical observation that 
the flux is linear in the gradient is follow as Fourier's law of heat conduction. 
ݍ" ൌ െ݇ డ்డ௫            (18) 
The diffusion coefficient is related to the product of the mean velocity of the molecules 
and the average distance between molecular interactions.  Notice that the diffusion 
coefficient has unit m2/s as does thermal diffusivity (α) and kinematic viscosity (υ).  The 
diffusion coefficient plays the same role in diffusion mass transfer processes that α and υ 
play in heat transfer and momentum transfer processes, respectively [59].    
 
2.2.4 Frequency Input Parameter to Eye for Passive Diffusion 
Previous research (Nickerson et al, 1963) [60] in the testing of the resonant 
frequency of the human eye showed a little effect at frequencies greater than 50Hz. They 
suggest that a maximum of 40Hz as the resonant frequency of the eye is reasonable to 
avoid abnormal vision. Since distortion of the sinusoidal input at lower frequencies 
makes very low frequency analysis, the lower limit of 5 Hz is the constraint limit. 
Incremental variations in frequency are enough to induce adequate diaphragm 
displacement while maintaining within safety limits for human subjects. Therefore if 
implant drug delivery device is not sufficient to provide the amount of therapeutic drug, 
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the structure of device including a membrane can be optimized to actuate from the 
external resonant vibration.    
 
2.2.5 Small Deflection of PDMS Membrane 
Since we consider the actuation manually at the beginning of the implant, a 
deflection of PDMS at the top of reservoir should be clarified to obtain the pressure and 
radius of forcing area. It is well known that solutions for small deflection of membrane 
theory. Small deflection in membrane theory is dominated by stresses in the plate [61]:  
ݓሺݎሻ ൌ   ௉௥೏మସఙ೔௛ ሾ1 െ ሺ
௥
௥೏ሻ
ଶሿ        (19) 
where w is the deflection of membrane, P is a uniform pressure on the surface of 
membrane,  σi is the intrinsic stress of a PDMS membrane, r, rd, and h are the radial 
coordinate, diaphragm radius, and thickness.   
The linear solution form for the deflection of a circular membrane under a uniform 
pressure and a pre-tension can be expressed by 
ݓ ൌ ݓ଴ሾ1 െ ሺ ௥௥೏ሻ
ଶሿଶ    (20) 
ݓ଴ ൌ ߝ ݎௗଷ ට௤௥೏ா௛          (21) 
where w0 is the maximum deflection at the center of the membrane, E, h, and ε are 
Young’s modulus, plate thickness, and Poisson’s ratio, respectively [61].  
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2.3 Design Concept  
In order to determine the width and depth of channels that enable a robust, 
convection-free diffusion, two different microchannel A and B are firstly investigated.  
Mircochannel is expected to work as the medium of the reservoirs. Since microchannel is 
located between reservoir and the outlet, it may reduce the back flow of drug or make 
more slow diffusion to contribute the velocity magnitude. The active microchannel is 
useful to control the diffusion rate under the some concentration difference, but its 
measuring process is complicated. The microchannel acts as a filter for drug particles 
transport and has simple structures compared to typical micro pore filters. It is easier to 
control reverse diffusion than micro-pore filters under the concentration difference. 
2.3.1 Single Straight Microchannel A 
To understand the microchannel behaviors under diffusion, we have developed 
simple microchannel models with single straight channel that mimic the actual amount of 
drug and volume of vitreous cavity. One single reservoir was connected to microchannel 
that has an inlet and an outlet. The whole structure had a height of about 2.5mm. The 
widths of the channels ranged from 100 µm to 1000 µm and the depth of the channel was 
65 µm. The channels acted as quasi-one-dimensional structures for diffusion. The 
schematic of single microchannel A is shown in Figure 2.1 that microchannel was 10mm 
long, and various widths (100, 250, 500, 750, and 1000 µm) are applied. The thickness of 
around 1.2 mm PDMS was covered on the top of the microchannel with a hole that was 
connected with a tube. The solution in reservoir could be exchanged via the microchannel 
with the outlet.  
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Figure 2.1 Design concept of single microchannel A being made of silicon wafer and 
covered with PDMS (Sylgard 184, Dow Corning) and tube (PTFE, 
PolyTetraFluoroEthylene, VICI AG International). 
  
2.3.2 Single Straight Microchannel B 
Two reservoirs were connected by channels of identical diameter. Each reservoir 
had an inlet and an outlet. The whole structure of reservoir had a height of 3mm and a 
diameter of 12mm. The widths of the channels ranged from a square of 200 µm to 1000 
µm. The schematic of single microchannel B is shown in Figure 2.2 that microchannel 
was 20mm in length, and various widths (100, 250, 500, 750, and 1000 µm) were applied. 
The thickness of around 1.2 mm PDMS was covered on the top of the microchannel with 
holes on both reservoirs. The solution in each reservoir could be exchanged via the inlets 
and the outlet. 
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Figure 2.2 Schematic of single microchannel B being made of Lexan® glass with 
machining. 
  
 
  
Table 2 Comparison of specifications between microchannel A and B 
Objects Microchannel A  Microchannel B  
Microchannel 
Length  
10 mm  20 mm  
Microchannel 
dimension  
Depth of 65 µm, 
100, 250, 500, 750, 1000 µm  
Square of  
200, 500, 750, 1000 µm  
Amount of drugs  5 µℓ  339.29 µℓ  
Solution  50 % of citric acid in a drug of eye multi- purpose solution (10g 
of citric acid is dissolved in 20ml of drug until all anhydrous 
crystalline is invisible)  
Amount of DI water  8580 µℓ (same amount of 
human eye vitreous fluid)  
339.29 µℓ  
Initial value of pH  Drug solutions include citric acids – 0.3 pH / DI water – 6.7 pH  
 
For measuring micro-particle image velocimetry, a test piece of microchannels 
including eight different sizes of channel was developed with one central located 
reservoir. The schematic of test piece of microchannels (Figure 2.3) shows that 
microchannel was 20mm long. Various two straight lined microchannels were a square of 
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250, 500, 750, and 1000 µm. The thickness of around 1.2 mm PDMS was covered on the 
top of the microchannel without a hole. The solution in each reservoir could be 
exchanged via the inlets and the outlet. 
 
 
Figure 2. 3 Schematic of test piece of microchannels (250, 500, 750, and 1000 µm width 
and depth) being made by Accura ®, Viper machine, 3D systems, for Particle Image 
Velocimetry. 
  
2.3.3 Various Geometry Microchannels 
Various microchannel geometries are developed to simulate the thermal diffusivity as 
shown in Figure 2.4. Four different micro-channels (type #1-4), which were straight, 
meshed, tournament, and osmotic, were developed to maintain a constant flow rate. 
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Figure 2.1 Various microchannels patterns considered for design analysis and simulation 
[62]. 
              
  
2.3.4 Device including Microchannels 
A novel implantable device incorporating microchannels was proposed for ocular 
drug delivery. As shown in Figure 2.6, the drug was stored in a reservoir at one end of the 
device. Microchannels were coated with hydrophilic coatings so that the drug from the 
reservoir diffused through the channels at specified/designed rate into the eye eliminating 
the need for any controlled actuation. 
In order to meet these characteristics, a unique design of an implantable micro-
channel for medical drug delivery system should be proposed. The design concepts of 
drug delivery device will consist of two layers of PDMS and micro-channel. Both upper 
and lower PDMS will be bonded through oxygen plasma process and filled with 
Hydrogels. Overall dimensions can be 1.5mm×1.0mm×max.1.0mm as shown in Figure 
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2.5. A schematic of the implantable drug delivery device in the eye in which reservoir 
will be made by PDMS and polymer resin - Accura ® 50 (3D system corp.) is illustrated 
in Figure 2.6.  In this study, the check valve was not applied in the drug delivery device; 
however, some micro-channels should be performed as its function of valve.   
 
Figure 2.2 Overall dimensions of present device [62]. 
  
 
 
Figure 2.3 Present device design concept for ocular drug delivery [62]. 
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Hydrogels (MIRAgel, MIRA Inc,Waltham,Mass), consisting of poly (methyl 
acrylate-Co-2-Hydroxyethyl acrylyte), are considered as means to passively induce the 
drug delivery into the microchannels so that the drug diffuses freely through the channels 
and reaches the outlet for delivery as a future work. The microchannel component with 
inlet/outlet reservoirs will be enclosed in a PDMS case whose base is rounded to match 
the curvature of the eye globe. The device is attached securely to the sclera of the eye 
with fine 10–0 or 9–0 nylon sutures. Ideally, the device would be surgically, transclerally 
implanted in the vitreous space with an external thin curved spherical surface flange that 
would be nearly flush with the sclera and sutured in place (see Figure 2.7).  
 
Figure 2.4 Overview of the attachment of the implanted drug delivery device to the eye 
[62] 
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The design requirements for the proposed drug delivery device are as follows: 
(i) target overall volume is less than 280mm3; 
(ii) diffusion rate is less than 0.07 nL/min; 
(iii) target diffusion time period will be around 1 to 2 years; 
(iv) kinetics: reliable diffusion coefficient of drugs through the microchannels; 
(v) implantable: eliminate repeated injections for effective treatment; 
(vi) actuation: sustained release drug delivery methods. 
 
2.3.5 Eyeball including Implanted Drug Delivery Device 
 
The diffusion model of drug movement in the eye can be depicted by Fick’s 
second law.  
பୡ
ப୲ ൌ
ப
ப୶ ቀD
பୡ
ப୶ቁ ൅ kୣc଴        (22) 
Where D is the diffusion coefficient or diffusivity in dimension of cm2/s, c is the 
concentration of drugs in the reservoir, and ke is drug elimination constant. 
 
In this study, we developed a diffusion model with a modified sphere eyeball for 
the pharmacokinetics of ocular drug delivery. The present model can predict the local 
velocity magnitude and pressure distribution as a function in time in the eye with 
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implantable delivery device. The diffusion coefficient of a drug across ocular tissues may 
depend on the chemical structure and the physicochemical properties as well as the 
molecular weight of the drug. The diffusion coefficient of a vitreous body (2x10-5 
cm2/sec) was observed by Tojo [50]. The diffusion coefficient in ocular tissues is mainly 
influenced by the molecular weight of the drug. The diffusion coefficient in the vitreous 
cavity is 10 times less than that in the aqueous humor.  
 
Figure 2.5 Schematic of a modified eyeball model with an implantable drug delivery 
device. The device is initially implanted as a perpendicular from a surface of eyeball. 
 
The macula, which is related the AMD disease, is located at the back of the eye 
and is aligned with a center line of lens as shown in Figure 2.8. The present model is 
developed with actual size of eyeball to evaluate the concentration distribution in the 
macula region. 
 
Macula
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2.4 Design Calculations 
To illustrate the targeted volume and rate of the drug delivery device, the 
following section provides the details of calculations. It has been assumed that drug-
contained deionized water will be transported through the microchannel from a reservoir. 
The corticosteroid fluocinolone acetonide has low solubility, so that solution was made 
by dissolving 59 mg of C24H30F2O6 in deionized water of 50 μL (concentration in the 
device ≈ 1.18 mg/μL). We also assumed that the concentration of drugs in the water 
within the reservoir was around 1.18mg/cm3 and concentration within the retina region of 
the eye was zero. Using this value of concentration, we could estimate the flux density of 
drug-contained water transport into the retina region by molecular diffusion. However, in 
this study, we assumed that the diffusion coefficient for typical eye drug, which is the 
corticosteroid fluocinolone acetonide in the deionized water, was equal to 2.5 × 10−7 
cm2/s. The concentration of drug in the reservoir was very large in comparison to the 
concentration in the retina region. To calculate the flux density, we use Fick’s Law (1), 
assuming that the gradient of concentration with length is linear over the microchannels 
path. The diffusive flux will be from the reservoir to the eye, from a high concentration to 
a lower concentration. 
It is a natural phenomenon that a substance goes from high concentration regions to 
low concentration regions. The movement of c(x, t) is called the flux of the population 
density, which is a vector. This principle is called Fick’s first law in one dimension, 
which relates the diffusive flux to the concentration and is given as, 
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J = −D* ∂c / ∂x  +  ke ·c                       (23) 
where, J is the diffusion flux (g/cm2·s), D is the diffusion coefficient or diffusivity in 
dimension of cm2/s, c is the concentration of drugs in the reservoir, and ke is a drug 
elimination constant. ke is not considered in this simulation because it may vary based on 
the property of drug and the absorption rate of drug in the human eye.   
Using, the above values, we get 
J = − 2.3 × 10−7 cm2/s · 1.18 g/cm3/0.8 cm 
= − 3.39 × 10−7 g/cm2· s.          (24) 
Ignoring the diffusion direction, we calculate the flux density of 3.39×10−7 g/cm2 
· s and it can be used to calculate the total mass flux of drug into the eye using (3) given 
below. For example, if the straight microchannel has an inlet area of 0.0005 cm2 with 12 
separate pathways, then the total flux into the eye is 
Mtotal = J × A,           (25) 
where, A is a section area at the inlet. 
Using the above values, we get  
Mtotal = 3.39 × 10−7 g/cm2 · s × 0.0005cm2 × 60 s/minute 
= 1.02 × 10−8 g/ min 
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≈ 1.04 × 10−4 μL/ min or 2.58mg/month (total 12 microchannels).    (26) 
As per our specification, the drug delivery device contains drug of 6mg in the deionized 
water, it can be continuously used for around 11 to 12 months without refilling injection 
[62]. 
In molecular diffusion, a transport of molecules varies linearly with respect to time for 
Fickian diffusion and a diffusion rate can be explained by  
Diffusion rate = J x A  
Substitute by Diffusion rate = - Ddiff × (Creservoir –Coutlet) / L × A              
Where, Ddiff = Drug diffusion coefficient (cm2/s), Creservoir = Concentration of drug in a 
reservoir (mol/cm3), Coutlet = Concentration of drug at the outlet (mol/cm3), L = Length of 
micro-channels (cm), and A is equal to area of micro-channel (cm2).  
Once we assumed that a diffusion coefficient of Brimonidine in water is 2.34 x 10-9 cm2/s, 
drug concentration changes at the outlet of device is divided by length of microchannel. 
Therefore, for instance, diffusion rate of straight channel can be calculated by 
 2.34 x 10-9  x ((0.273879 – 0) /1) x 0.05 x 0.0065  = 2.082 x 10-13 (kmol/s).  
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2.5 Similarity with Scale Up Model 
Even though the implantable device is at a micro-scale, a scaled up millimeter-
device from micro-scale to millimeter scale model (from 10 µm to 1 mm) was developed 
in this investigation. This is due to our ultimate objective of developing a micro-fluidic 
drug delivery device (1 nL/s ~100 nL/s) mimicking the overall microchannel geometry 
configuration. Table 2.2 lists the various parameters (length, diameter, water density, and 
viscosity) of the nano-scale biological motor and the present microchannel B model. 
The similarities between the nano-scale biological device and the present micro-device 
are shown in Table 2.3. As can be seen from Table 2.3, we kept the geometric similarity 
to be 1 so that the continuum mechanics were held and the results of velocities and flow 
rate would be similar between the nano-scale and millimeter scale considered. In order to 
further illustrate this aspect, a nano-scale model was built and the results were compared 
to those obtained by the micro-scale model. In general, the results from the millimeter 
micro-device model were applicable to the nano-scale model with the scaled up ratio (λ) 
and the trends were also similar. In addition, surface area is another factor that becomes 
important at the micro-scale. As an example, a 35 mm diameter beaker half full of 2.5 
mL water had a surface area to volume ratio of 4.2 cm-1, whereas a microchannel 50 µm 
tall, 50 µm wide, and 30 mm long, a 75 nL volume, had a surface area to volume ratio of 
800 cm-1. When going from the macroscale to the microscale, an increase in the surface 
area to volume ratio by orders of magnitude is not uncommon. A very large surface area 
to volume ratio makes capillary effect more efficient in microchannels [63]. 
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Table 3 Various parameters used in the present microchannel B model in comparison to 
nano-scale biological device [63]. 
  
  
Table 4 Dimensionless similarities between nano-scale biological device and the present 
micro-scale model of microchannel B. 
 
 
2.6 Hydrophobic and Hydrophilic   
Hydrophobic molecules tend to be non-polar and thus prefer other neutral 
molecules and non-polar solvents. Hydrophobic molecules in water often cluster together 
forming micelles. Water on hydrophobic surfaces will exhibit a high contact angle. 
In general, a hydrophobic surface that has an original contact angle greater than 90° 
becomes more hydrophobic when microstructured – its new contact angle becomes 
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greater than the original. However, a hydrophilic surface that has an original contact 
angle less than 90° becomes more hydrophilic when microstructured – its new contact 
angle becomes less than the original. 
 
A liquid droplet rests on a solid surface and is surrounded by air. From Figure 2.8, the 
contact angle, θC, is the angle formed by a liquid at the three phase boundary where the 
liquid, air, and solid intersect.   
 
 
Figure 2.6 Schematic overview for the contact angle between water droplet and PDMS 
surface; θC is the contact angle, BAW is the boundary line between air and water following 
BAP - air and PDMS, BPW- PDMS and water.  
 
 
2.7 Discussion 
In a liquid, every atom is in random motions and these random motions produce 
both diffusion and viscous flow when the motions are driven by a force. The Fick’s law 
depicts that the diffusion occurs when molecular particle in high concentration moves 
forward to low concentration region. 
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The design of an implantable drug delivery device and experimental models 
should be comparable to verify the diffusion rate and drug releasing time. Although the 
diffusion coefficient of a drug may depend on the chemical structure and the 
physicochemical properties as well as the molecular weight of the drug, a consistent 
boundary condition and various size of microchannel are mainly focused to manipulate 
the diffusion rate and to obtain the best fit of microchannel geometry.  Although the 
diffusion rate is calculated based on the diffusion coefficient of 2.5 × 10−7 cm2/s and flux 
density of 3.39×10−7 g/cm2 · s, the rate of diffusion may change with respect to time. The 
single straight microchannel A and B have developed to investigate the diffusion 
characteristics in the microchannel. Both microchannel A and B have a different cross 
section area of microchannel and length to ensure that the diffusion rate are proportional 
to the size of microchannel and adversely proportional to the length of microchannel. 
The similarities between the nano-scale biological device and the present micro-
device are discussed to understand the continuum mechanics and the results of velocities. 
The molecular flow rate will be similar at the nano-scale and micrometer scale. 
 
2.8 Summary 
Based upon the theoretical background of the diffusion, several straight 
microchannels were developed to analyze the diffusion coefficient in associate with 
dimension of microchannel. Two different microchannels were firstly investigated such 
as microchannel A and B.  Mircochannel was expected to work as a medium of reservoir. 
Since microchannel was located between reservoir and the outlet, it may reduce the back 
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flow of drug or make more slow diffusion to contribute the velocity magnitude. An 
implantable drug delivery device integrated microchannel may be suitable for a practical 
application with free diffusion.  
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CHAPTER 3 Simulations for Microchannels and Devices 
3.1 Introduction 
To understand the characteristics of diffusive drug delivery through the proposed 
microchannel design, three-dimensional flow characterizations were conducted using 
combined computational fluid dynamics (CFD) analysis based on Eulerian-Lagrangian 
methods. Computational fluid dynamics is became a leading component in microfluidic 
device design by providing predictions of device performance for a variety of research 
focuses. With increases in computational resources and numerical techniques, the 
accuracy and scope of CFD applications are rising. For microfluidic devices such as 
micro-pump, micro-value, micro-dispensing, and micro-spotter, CFD could provide cost-
effective insight into device performance compared with conventional prototyping, 
manufacturing and experiments. [64 - 69, 71]  Over the couple of decades, numerical 
analysis of the diffusion flow using CFD have been utilized for evaluating characteristics 
of microchannel designs such as diffusion coefficient, pharmacokinetics, and molecular 
particle transport properties [72, 73]. With adjustments in simulated boundary and 
diffusion conditions, parameters influencing diffusion coefficient are easily modified to 
obtain a device with desired properties. In this research, the finite element method was 
performed for the microchannel A, microchannel B, entire device, various geometry 
microchannel, and eyeball with implantable device using ANSYS V12 – Fluent and 
COMSOL multiphysics. COMSOL has a flexible platform that allows modeling all 
relevant physical aspects of model designs. It is useful to develop customized solutions, 
  52 
applicable to unique circumstances. When starting a new project, using COMSOL 
Multiphysics helps to understand its several problem solving. User can perform to test out 
various geometrical and physical characteristics of diffusion model in order to obtain the 
important design challenges. 
Currently the only approach available to users is a trial-and-error approach that 
requires large numbers of experimental tests or numerical simulations. The numerical 
simulations typically involve unacceptably long computation time and are limited by 
algorithmic stability. For example, accurate simulations of microchannel diffusion at the 
various geometry regions by finite volume approaches become very difficult due to errors 
associated with numerical diffusion, unless extremely fine meshes are used. To address 
these issues, several modified form models have been developed for diffusion coefficient.  
 
3.2 Single Straight Microchannel A 
3.2.1 Governing Equations and Computational Methods 
The general form of the diffusive transport equation for additional variable is 
డሺఘ׎ሻ
డ௧ ൌ ߘ · ሺߩܦ௖ߘ׎ሻ ൅ ܵ׎       (27) 
By substituting the conserved quantity, ׎ ൌ ௖ఘ, we get  
డ௖
డ௧ ൌ ߘ · ሺܦ௖ߘܿሻ ൅ ܵ௖/ఘ       (28) 
Where ρ is the mixture density, mass per unit volume, c is the conserved quantity 
per unit volume, or concentration, Sc/ρ is a volumetric source term, with units of 
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conserved quantity per unit volume per unit time, and Dc is the kinetic diffusivity for the 
scalar. 
3.2.2 Computational Models and Boundary Conditions 
The first step to begin this analysis was to create a three-dimensional fluid model 
of the single straight microchannels using modeling software, which was the SolidWorks 
(Dassault Systèmes SolidWorks Corporation, Waltham, MA). Once a three dimensional 
fluid model of the single straight microchannels was completed, this fluid model may 
work to convert a solid model of structural compartments. (Figure 3.1).  
ANSYS Workbench software was the unifying graphical user interface to the 
multitude of ANSYS simulations, which were predominantly based on implementations 
of the finite element method and computational fluid dynamics. This workbench had a 
Fluent analysis function includes a design modeler, meshing and defining a boundary 
surface, and CFD-post. These functions were used to develop the three-dimensional 
model of the microchannel and reservoir geometry. In this study, the three-dimensional 
fluid model then was imported into design modeler with a parasolid format and meshed 
(Figure 3.2). This software allowed the mesh to be generated and created, which was a 
standard preprocessor for ANSYS-Fluent software. Due to symmetry, only one half of 
the domains were constructed. A structural hexahedral mesh was employed to provide a 
high quality flow field solution. 
The ANSYS Fluent utilized finite volume based methods to mathematical solve 
non-linear partial differential equations and simplified them into a system of algebraic 
equations which were solved numerically through various iterations. Values derived from 
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the fluent usually experienced discretization using central difference methods and in most 
instances were second-order accurate in diffusion terms. 
The segregated solver was chosen and mainly utilized for flow that was 
incompressible where the resulting algebraic equations were solved sequentially as 
opposed to the couple solver which solved the algebraic equations simultaneously due to 
the inter-dependence of scalars associated with the flow field. The model was also 
laminar which results in no energy equation being solved. The fluid was set as water-
liquid with the corresponding properties: Density, ρ: 998.2 kg/m3 and Viscosity, μ: 1x10-3 
kg/m-s, diffusion coefficient, D: 2.5 x 10-7cm2/s.  
The inlet boundary condition at the top of the reservoir was a diffusion 
logarithmic form, which was produced by pH value with respect to time in the first 
diffusion experiments. The properties of drug are assumed to be those at 27 °C.  No 
pressure outlet of the fluid domain was applied. A no-slip boundary condition was 
applied at the fluid-solid interface. Figure 3.1 shows the finite element model and all 
boundary conditions of the single straight microchannel A.  
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Figure 3. 1 Finite element model and all boundary conditions of straight microchannel A, 
denotes the number of elements and nodes for each microchannel size. 
The model solution methods were set as variables for pressure-velocity coupling 
schemes as well as the method of computing the gradient in Least Squares Cell Based 
Flow which contained the discretization schemes available for the pressure and 
momentum equations: first order upwind and second order upwind. 
3.2.3 Diffusion Motion 
A user-defined function written in the C programming language was used to 
manipulate the movement of the particle at the inlet which located on top of the reservoir. 
The uniform diffusion was set on top of the reservoir, which was governed with the 
following expression in order to create the periodic velocity changes associated with the 
diffusion coefficient and the logarithmic changes that we obtained from the first 
measurement: 
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This program was utilized and defined to the diffusive velocity at the inlet, which 
allowed one to determine the diffusion characteristics of the fluid. The expected 
operating method of the diffusion was to travel particles (or fluid) from inlet to outlet, 
which was studied for all the microchannel models. 
3.2.4 Model Validation 
Most CFD applications in microfluidic devices investigated steady-state and 
transient conditions such as pressure distribution and velocity fields. Pathlines and 
streamlines yield information as to how diffusion flowed through microchannels and 
variances in fluid velocities, particle residence time, and pressure contours have been 
used to assess global uniformity of the flow field. 
It is well known that non-uniform diffusion characteristics were undesirable, and 
it is often believed that flow path heterogeneities could lead to inactive diffusion flow. 
Likewise, single straight microchannels were designed to achieve uniform flow 
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distribution in order to eliminate significant factors of pressure and concentration changes 
from the geometric configurations, and to optimize diffusion efficiency. 
A mesh-independence study was performed on the solid and fluid domains to 
confirm that a fine enough element had been used to represent both solid and fluid 
domains. The mesh-independence study begun with a mesh discretization and recorded a 
solution. Then the finer elements were used to represented fluid domains. The results 
from the finer-element model were then compared with those from the first model. If the 
results were nearly similar, then the first mesh was probably good enough for that 
particular geometry, loading and constraints. If the results differed by a large amount, the 
process was repeated with the finer elements. Maximum pressure and velocity were used 
as convergence criteria for the fluid domain. A converged model was obtained when 
changes in those solutions were less than 5%. Having performed the mesh-independence 
study, the diffusion velocity from the finite element model for a single divergence was 
then compared to the experiment by single straight microchannel A. 
3.2.5 Diffusion model in COMSOL 
The transient analysis of diffusion in 2D was performed according to 
concentration changes while using COMSOL multiphysics. The diffusion coefficient D 
and concentration changes with respect to time were a variable for this analysis. The 
other boundary condition and temperature were a constant.     
Boundary condition;  C0 = 1, at the reservoir 
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C0 = 0, at the microchannel and outlet 
D = 2.34 x10-9 cm2/sec 
C0,t = D*(-0.028*log(t[1/s]) + 0.8972 
 
Figure 3. 2 Geometry and boundary conditions of microchannel A in COMSOL  
 
3.3 Single Straight Microchannel B 
3.3.1 Governing Equations and Computational Methods 
The general form of the diffusive transport equation for additional variable was applied 
same as governing equation of previous microchannel A.   
డ௖
డ௧ ൌ ߘ · ሺܦ௖ߘܿሻ ൅ ܵ௖/ఘ         (29) 
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3.3.2 Computational Models and Boundary Conditions 
Once a three dimensional fluid model of the single straight microchannel B was 
completed, this fluid model may work to convert a solid model of structural 
compartments. (Figure 3.2).  
The segregated solver was chosen and mainly utilized for flow that was 
incompressible. The model was also laminar which results in no energy equation being 
solved. The fluid was set as water-liquid with the corresponding properties: Density, ρ: 
998.2 kg/m3 and Viscosity, μ: 1x10-3 kg/m-s, diffusion coefficient, D: 2.5 x 10-7cm2/s.  
The inlet boundary condition of the fluid domain was a diffusion logarithmic 
form, which was produced by pH value with respect to time in the first diffusion 
experiments. A pressure accounting at the outlet of the fluid domain was applied as zero. 
A no-slip boundary condition was applied at the fluid-solid interface. Figure 3.2 shows 
the finite element model and all boundary conditions that were applied same as the single 
straight microchannel A.  
 
Figure 3. 3 Finite element model and all boundary conditions of straight microchannel B, 
denotes the number of elements and nodes for each microchannel size. 
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Again, same as like microchannel A, the model solution methods were set as 
variables for pressure-velocity coupling schemes as well as the method of computing the 
gradient in Least Squares Cell Based Flow which contained the discretization schemes 
available for the pressure and momentum equations: first order upwind and second order 
upwind. 
 
3.4 Various Microchannel Configurations 
3.4.1 Governing Equations and Computational Methods 
The ANSYS Multiphysics product supported a transient thermal analysis. 
Transient thermal analysis determined temperatures and other thermal quantities that vary 
over time. We commonly used temperatures that a transient thermal analysis calculated 
as input to structural analyses for thermal stress evaluation or diffusion simulation 
because the preliminary equations were identical. A transient thermal analysis followed 
basically the same procedures as a steady-state thermal analysis. The main difference was 
that most applied loads in a transient analysis were functions of time. To specify time 
depend loads, we used the function tool as a boundary condition.  
The first law of thermodynamics stated that thermal energy was converged. 
Specializing this to a differential control volume: 
ߩ݄ ቂడ்డ௧ ൅ ሼݒሽ்ሼܮሽܶቃ ൅ ሼܮሽ்ሼݍሽ ൌ ݍഺ      (30) 
where ρ is density of the fluid, h is specific heat, T is temperature, and t is time. 
{L} is a vector operator and {v} is a velocity vector for mass transport of heat 
ݒ௫ 
ݒ௬ 
ݒ௭ 
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{L} =    డడ௫ 
ങ
ങ೤ 
ങ
ങ೥
                {v} =        (31) 
 
Where {q} is heat flux vector, and qഺ is a heat generation rate per unit volume.   
 
3.4.2 Computational Models and Boundary Conditions 
Microchannel pattern was considered to be also provided by the recent reviews on 
the application of microfluidic lab-on-a-chip platforms [74, 75]. The first step to begin 
this analysis was to create a three-dimensional fluid model of four different microchannel 
configurations using modeling software, which was the SolidWorks. Once a three 
dimensional fluid model of different microchannel configurations was completed, this 
fluid model may work to convert a solid model of structural compartments (Figure 3.3). 
The overall dimensions of microchannels were within a range of 1.5 ׽ 8.0mm in length, 
had a depth of 5 to 100 μm and a width may vary based on the geometry of 
microchannels (50 ׽ 500 μm) as shown in Figure 3.3 
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Figure 3. 4 Finite element model and all boundary conditions of various microchannel 
configurations, denotes the number of elements for each microchannels [62]. 
In order to understand the design characteristics of the microchannels, we 
developed a coarse-grained representation of the microchannel geometry through 
computational fluid dynamic analysis and optimization. Specifically, the role of the 
microchannel geometry in passive free diffusion that molecules could pass freely through 
the microchannel follow concentration gradients was investigated and discussed. Figure 
3.6 shows the finite element model and all boundary conditions that were used for the 
various microchannel configurations. Finite element (FE) analysis using ANSYS-
Multiphysics module was used to perform the design simulations. Four different 
microchannel geometries were developed to simulate the thermal diffusivity as shown in 
Figure 3.3. Drug concentration at the reservoir was assumed to be 1 kmol/m3 and drug 
concentration at the outlet to be 0 kmol/m3. This concentration represented drug 
concentration in the eye. Drug diffusivity was assumed to be the same as the synthetic 
corticosteroid Fluocinolone acetonide in deionized (DI) water (2.3 × 10−7 cm2/s) [22]. 
The properties of fluid material;  
Density:  ρ = 998 kg/m3  
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Viscosity: µ = 0.001  
Conductivity: k = 0.6 W/m-K  
Specific Heat: hp = 4181.3 J/kg-K  
Element type:  Thermal -3D SOLID 90 
Boundary conditions: 60˚C at the inlet wall, 37.5˚C at the outlet wall and other 
fluid walls  
 
3.5 Drug Delivery Device include Microchannels 
3.5.1 Governing Equations and Computational Methods 
The general form of the diffusive transport equation for additional variable is applied 
same as governing equation of previous microchannel A.   
డ௖
డ௧ ൌ ߘ · ሺܦ௖ߘܿሻ ൅ ܵ௖/ఘ        (29) 
3.5.2 Computational Models and Boundary Conditions 
Once a three dimensional fluid model of the microchannel configurations was 
completed, this fluid model may work to convert a solid model of structural 
compartments. (Figure 3.4).  
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Figure 3. 5 Solid model of microchannel configuration within the device using 
Solidworks 
The segregated solver was chosen and mainly utilized for flow that was 
incompressible. The model was also laminar which results in no energy equation being 
solved. The fluid was set as water-liquid with the corresponding properties: Density, ρ: 
998.2 kg/m3 and Viscosity, μ: 1x10-3 kg/m-s, diffusion coefficient, D: 2.5 x 10-7cm2/s.  
The inlet boundary condition at the top of reservoir was a diffusion logarithmic 
form, which was produced by pH value with respect to time in the first diffusion 
experiments. A pressure accounting at the outlet of the fluid domain was applied as zero. 
A no-slip boundary condition was applied at the fluid-solid interface. Figure 3.5 shows 
the finite element model and all boundary conditions that were applied same as the single 
straight microchannel A.  
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Figure 3. 6 Finite element model and all boundary conditions of various microchannel 
configurations within the device, denotes the number of elements for each microchannels. 
 
3.5.3 Diffusion model in COMSOL 
The transient analysis of diffusion in 2D was performed according to 
concentration changes while using COMSOL multiphysics. The diffusion coefficient D 
and concentration changes with respect to time were a variable for this analysis. The 
other boundary conditions and temperature were a constant.     
Boundary condition;  C0 = 1, at the reservoir 
C0 = 0, at the microchannel and outlet 
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D = 2.34 x10-9 cm2/sec 
C0,t = D*(-0.028*log(t[1/s]) + 0.8972 
 
Figure 3. 7 Geometry and boundary conditions of device in COMSOL  
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3.6 Results 
3.7.1 Effect of Microchannel A 
 
Figure 3. 8 Simulation results of maximum velocity magnitude for five different 
microchannels, data is observed at the outlet of microchannel A. 
 
The results of maximum velocity magnitude for five different microchannels 
showed that a smaller cross section of microchannel had higher velocity magnitude than 
small one (Figure 3.9). The velocity magnitudes were adversely nonlinear to the size of 
microchannel. It can be assumed that a modeling the various size of microchannel 
properly played an important role in the prediction of microchannel efficiency. 
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Figure 3. 9 Simulation results of velocity profiles for four different microchannels, data is 
observed at the inlet, middle, and outlet of microchannel A. 
 
The above Figure 3.10 shows the comparison of the simulation results of velocity 
profiles for each microchannel. The microchannel size influenced the diffusivity all through 
microchannel coordination.  However since there was no slip boundary condition, the wall 
slip velocity was about zero. The slip velocity at wall was much smaller then that at the 
channel center. The flow velocity profile along horizontal central line y (m) of channel 
section for all microchannel size was shown in Figure 3.10. 
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Figure 3. 10 Simulation results of diffusion rate at one second for five different 
microchannels. 
  
 
 
Figure 3. 11 Simulation results of diffusion rate at ten seconds for five different 
microchannels. 
  
 
The above Figure 3.11 and 3.12 show the comparison of the simulation results of 
diffusion rate at 1 and 10 seconds for each microchannel. The diffusion rate increase along 
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the microchannel size increase, as previously predicted by diffusion equation 28. The 
variations of diffusion rate showed linearly decreasing with respect to time for 10 seconds.  
 
 
 
Figure 3. 12 Simulation results of velocity differences at one second for five different 
microchannels. 
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Figure 3. 13 Simulation results of velocity differences at ten seconds for five different 
microchannels. 
  
 
Figure 3.13 and 14 show that the velocity differences between inlet and outlet at 1 
and 10 seconds explained small microchannel size generated relatively high resistance for 
the diffusion. The diffusive velocity difference increased with decrease of the 
microchannel size. Similarly the change of velocity difference reduced along the time 
goes on.  
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Figure 3. 14 Simulation results of pressure differences at ten seconds for five different 
microchannels. 
 
  
The relationship of the pressure difference of the microchannel size is shown in 
Figure 3.15. The microchannel size increased with decrease of the pressure difference. 
Similar behaviors were found for diffusion rate. It indicated that the decreasing 
microchannel size enhanced the viscous effects on diffusion flow when pressure gradient 
was constant. 
 
3.7.2 Effect of Microchannel B 
The maximum velocity magnitude of microchannel is shown in Figure 3.16. The 
rest of parameters which were the relationship of the pressure, velocity difference with 
time variations against microchannel size were the same as the microchannel A.  
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From the velocity profile (Figure 3.17), we can be assumed that slowed diffusion 
also generate a parabolic curve along the channel length because it was similar as 
incompressible and laminar flow in the channel. Although diffusion was a molecular or 
viscous flow, velocity profiles and maximum velocity with microchannel size showed 
similar behaviors as small volume fluid flow. 
 
 
Figure 3. 15 Simulation results of maximum velocity magnitude for four different 
microchannels, data is observed at the outlet of microchannel B. 
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Figure 3. 16 Simulation results of velocity profiles for four different microchannels, data 
is observed at the inlet, middle, and outlet of microchannel B. 
 
Again, the above Figure 3.17 shows the comparison of the simulation results of 
velocity profiles for each microchannel. The microchannel size influenced the diffusivity all 
through microchannel coordination.  However since there was no slip boundary condition, 
the wall slip velocity was about zero. The slip velocity at wall was much smaller then that at 
the channel center. The flow velocity profile along horizontal central line y (m) of channel 
section for all microchannel size was shown in Figure 3.17. 
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Figure 3. 17 Simulation results of diffusion rate at one second for four different 
microchannel B. 
  
 
 
Figure 3. 18 Simulation results of diffusion rate at ten seconds for four different 
microchannel B. 
  
Again, the above Figure 3.18 and 3.19 show the comparison of the simulation results 
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along the microchannel size increase, as previously predicted by diffusion equation 28. The 
variations of diffusion rate showed linearly decreasing with respect to time for 10 seconds. 
 
Figure 3. 19 Simulation results of velocity differences at ten seconds for four different 
microchannel B. 
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Figure 3. 20 Simulation results of pressure differences at ten seconds for four different 
microchannel B. 
  
Due to high ratio of channel cross section area in comparison with microchannel 
A, the pressure difference and velocity difference were proportionally increase or 
decrease along the microchannel size as shown in Figure 3. 20 and 21. The results of 
diffusion rate with different size of microchannel showed a consistent agreement with the 
principle equation of diffusion. 
 
  
3.7.3 Effect of Microchannel Configurations 
The length of microchannels depended on the geometry of diffusion channels. 
Several simulations of drug diffusion rates from various microchannel configurations 
were carried out. The result of molecular diffusion rate through typical straight 
microchannels was shown in Figure 3.22. The length and width of the straight 
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microchannel for this simulation were 8mm and 500 μm. Initially, there was a drastic 
increase and after a certain time while the diffusion rate was almost constant. 
 
Figure 3. 21 Simulation results of drug diffusion through a straight type micro-channel 
configuration [62]. 
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Figure 3. 22 Simulations of drug diffusion at 50 seconds through various microchannel 
configurations [62]. 
 
  
Flow field reached at the end of the channel within 38 seconds. Fully developed 
flow, with sustainable diffusion rates, occurred at approximately 150 seconds. The results 
of drug diffusion at 50 seconds through various microchannel configurations considered 
are shown in Figure 3.23. It was interesting to note that different microchannel 
configurations would give rise to different diffusion rates.  
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Figure 3. 23 Molecular diffusion rate for various microchannel configurations considered. 
  
 
The drug diffusion rate as a function of time for various microchannel 
configurations was presented in Figure 3.24. It can be seen from Figure 3.24 that each of 
the microchannel configurations exhibited different diffusion characteristics in terms of 
drug diffusion rates. Initially, there was a drastic increase and after a certain time while 
the diffusion rate was almost constant. If the drug was to be delivered at a constant rate 
over a one-hour period then the inlet flux of straight microchannel would be 6.25 × 10−12 
kmol/s. Over the first second, there was a rapid increase of diffusion rates up to 
approximately 1.24 × 10−13 kmol/s and then a more gradual increased to approximately 6 
× 10−12 kmol/s after 105 seconds. Overall, each of the microchannel configurations could 
deliver the drug at different diffusion rates. 
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3.7.4 Effect of Device with Microchannels 
Simulation results of drug diffusion within the microchannels as a function of 
time and drug diffusion from the drug reservoir to opposite site revealed high-
concentration area to zero drug concentration area. The diffusion coefficient was 
dependent on the time factor as well as microchannel size and drugs. Figure 3.25 showed 
that the simulation results of velocity vector for four different microchannel 
configurations were presented. All the microchannels generated the maximum velocity at 
the critical flow bending region or narrow region. However, a range of the velocity 
magnitude was relatively small (3.3 - 4.2 x 10-7 m/s) based on small variations of the 
cross section area of each microchannel. 
 
     
 
Figure 3. 24 Simulation results of velocity vector for various microchannel configurations. 
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 Results of velocity magnitude as a function of time were performed for four 
microchannel configurations. It can be seen in Figure 3.26 that the velocity magnitude of 
osmotic microchannel was smaller than the other channel configurations. It was assumed 
that the   diffusion length and resistance from two directional flow of osmotic channel 
may affect the velocity magnitude with respect to time.   
 
 
Figure 3. 25 Simulation results of velocity magnitude as a function of time for various 
microchannel configurations. 
 
 
3.7.5 Effect of Microchannel A using COMSOL 
The boundary condition of outlet reservoir was axial symmetry along the center 
axis of entire volume in 2D model. Values for diffusion coefficients and rate constants 
came from the literature, Heeren A. et al [72] and experiment results.  
Figure 3.31 showed that the concentration transients of the free diffusion species 
through 250 and 500 µm microchannel A. The initially rate of diffusion of each channels 
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quickly increased until around 2.5 hours and then seemed to get a gentle slope when it 
was a stable diffusion. The effect of device included different size of microchannel was 
clearly visible; concentration increasing with time goes on. 
 
 
Figure 3. 26 Results of concentration changes at the ahead of outlet reservoir for 24 hours 
in microchannel A. 
 
3.7.6 Effect of Device includes Microchannels using COMSOL 
Figure 3.32 shows that the concentration of drug across the modeling domain 
through various geometries of microchannel in a device. The initially rate of diffusion of 
each channels quickly increased until around 2.0 hours and then seemed to get a gentle 
slope when it was a stable diffusion, which was similar behavior with simulation of 
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microchannel A. The effect of device includes different geometry of microchannel was 
clearly visible, concentration increasing with time goes on. 
 
 
Figure 3. 27 Results of concentration changes at ahead of outlet reservoir for 24 hours in 
a device. 
 
Figure 3.33 showed that the diffusion rate of each microchannel was calculated based on 
the concentration changes with respect to time (T1, T2) at the outlet reservoir. T1 and T2 
were selected as a transition period between steepest slope and gentle slope.  
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Figure 3. 28 Comparison of Diffusion rate at T1 and T2 with four microchannel 
configurations  
 
3.7 Discussion  
The effects of the microchannel A and B were investigated in correlation with 
diffusive velocity and pressure changes at each time step. Based on the results obtained 
through microchannel A, B, various microchannel configurations, the microchannel was 
suitable to control the diffusion rate for the developed ocular drug delivery device. In 
order to demonstrate the diffusion through the microchannel and entire device, an 
analysis was carried out using different size of microchannel and reservoirs. The results 
of diffusion rate at various times for all microchannels were investigated. Very slow 
diffusion occurred most likely at the narrow and small channel paths. This demonstrated 
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that the developed microdevice was capable of delivering the drug through the 
microchannel configuration. The results obtained from the simulations confirmed that the 
microchannels had the potential to be used as a drug delivery system depending on 
desired flow rates and drug concentrations. Since drug consumption occurred at the blood 
vessel of a vitreous body which could be approximated as zero, the amount of diffusion 
may vary with the concentration gradient; however, a constant drug release rate could be 
obtained. The proposed device could produce a constant delivery rate, which was 
favorable to the treatment of eye disease.  
 
3.8 Summary  
A microdevice concept for ocular drug delivery was proposed in this chapter. The 
design involved development of an implantable device with micro-/nanochannels with 
top and bottom covers.  
Single straight microchannels were designed to achieve uniform flow distribution 
in order to eliminate significant factors of pressure and concentration changes from the 
geometric configurations, and to optimize diffusion efficiency. Straight microchannel A 
and B were performed the simulation to obtain the velocity magnitude and pressure 
changes. Diffusion rates were calculated based on the diffusion coefficient with respect to 
time for each microchannel. Four different channel configurations were developed and 
analyzed for their diffusion characteristics. Diffusion rates could be customized to obtain 
effective levels by varying height, width, and length of microchannels.  
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CHAPTER 4 Fabrications and Testing 
4.1 Introduction  
In order to illustrate the proof of concept, straight and various microchannel 
configurations were etched on the silicon substrate using photolithography technology. 
To build a functional microfluidic device or a “lab-on-a-chip”, one must effectively 
integrate components such as microchannels, valves, and reservoirs. This section 
described fabrication of functional microfluidic devices for applications in drug delivery. 
We focused on PDMS-based systems, for which substantial progress had been made on 
the integration of components, because they both allowed rapid prototyping and served as 
final functional devices. Microfluidic components had been integrated using other 
materials to build impressive devices for drug delivery [31]. 
 
4.2 Fabrication of PDMS  
Master molds for both upper and bottom layers of the reservoir were made of 
Acura 50 plastic (3D system corp.) and constructed from 3D stereolithography process 
using 3D Viper SLA system (3D system corp.). PDMS [76, 77] was mixed silicone 
elastomeric base and a curing agent with a 10:1 ratio (SYLGARD 184, DOW 
CORNING) and poured into a mater mold. The resulting PDMS was peeled from the 
master mold. The second molding step was then performed by pouring a mixture of 
Sylgard PDMS and curing agent over the master mold. A mold release material, water 
base white peelable barrier coat (Berkley, Akron, PA, USA), was placed at the surface of 
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the master mold prior to pouring to allow simplistic separation between the PDMS and 
master mold.  
The PDMS was degassed in a vacuum machine for 20 minutes (Durable medical 
equipment Inc., Richmond, VA). Using a vacuum chamber on the PDMS material 
allowed removing all of the air bubbles from the polymer to provide for a smooth, air 
bubble free volume. Removal of air from the PDMS was crucial to ensure there were not 
defects that would cause sealing issues while bonding and testing. The PDMS cured at 
room temperature for 24 hours or 80◦C for 2 hours. Semi-cured PDMS as the bonding 
technique was suitable for bonding the microfluidic devices. The bond strength was close 
to that of bulk PDMS.  
The fabrication process for the PDMS (Figure 4.1) was a straight forward 
procedure, but there were some alternate steps depending on how much strength of the 
PDMS material to produce. After the PDMS had been poured the molds were placed into 
an oven. The oven temperatures could range to 75 degrees Celsius. The mold was baked 
for one-hour and then removed from the oven. During a twenty-four hour period it was 
left to cure at room temperature. Following removal from the oven, the PDMS could be 
removed from the master mold. Removing the PDMS from the master mold was simple, 
but care must be exercised because a polymer could rip and tear with ease. Once the 
fabricated PDMS covers had been removed from the molds, they could experience the 
bonding process.   
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Figure 4.1 Fabrication process for PDMS. 
 
4.3 Fabrication of Microchannels  
The microchannel geometries were formed using soft lithography on the 4” 
silicon wafers after baking at 1000◦C for at least 10 hours to get at least 1 μm thickness of 
an oxides layer. The wafers were vapor coated with hexamethyldisilazane (HMDS) 
adhesion promoter. After the mask was completed, photoresist (AZ ECI #3012, AZ 
Electronic Materials, Branchburg, NJ, USA) was poured on the wafer around 2.5mL and 
spin coated at 4000 rpm for 30 s (expected thickness less than 0.8 μm layer), and then the 
wafer was baked at 90◦C for 1 minute. After exposure, native oxide was removed with a 
20% KOH solution dip at 80◦C for 2 hours and 5 hours so that 100 and 250 μm etch 
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depths for the microchannels would be achieved. The final step of the wafer fabrication 
was to remove the oxide by using a BOE etch. The following microchannel fabrication 
process was shown in Figure 4.2.  
 
Figure 4. 2 Fabrication process for Silicon substrate. 
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Figure 4. 3 KOH etching rate of 100 Si at 70 ˚C. 
  
 
Figure 4. 4 Microchannel depth profiles of width of 100µm and 1000 µm after KOH 
etching for 5 hours. 
When the microchannel was completed on the silicon substrate, the etching rate of 
KOH was obtained through the Dektak 150 surface profiler (Figure 4.3 and 4.4). It can be 
seen in Figure 4.4 that the microchannel had not formed exactly a rectangular shape and 
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easily break with over 100µm depth or over 3hours of KOH etching. Majority of 
microchannels had very rough surface on the bottom of channel; around 12 µm 
roughnesses. The widths of 100 µm microchannel could not achieve a full depth. It 
suggested that a width of microchannel should be greater than 100 µm with over 12 µm 
depth.   
 
4.4 Oxygen Plasma Bonding  
Oxygen plasma technology was inclusive of many different purposes for surface 
treatment such as cleaning, coating, printing, painting, and adhesive bonding.  Plasma 
technology had become to encompass so many different applications that it was now one 
of the top methods in surface treatment, especially in microelectronics and packaging 
industries. Since plasma treatment added another step to the bonding process, there was a 
tendency to reduce or even eliminate it all together. However, in general, the level of 
plasma treatment used should be the minimum amount that gave a reproducible bonded 
part having the desired level of performance. The pretreatment process consisted of three 
segments: cleaning, activation, and surface bonding.  These steps were an extremely 
important part of plasma treatment because it directly affected the quality of the surface 
in which adhesive would later be applied.  Cleaning the substrate surface could be done 
using a plasma system to remove even the finest particles of dust.  The plasma actually 
consumed many of the particles through the surface reaction and completely removed 
them from the substrates.   
  93 
Tang et al [57] studied how the bonded area varied under different plasma power 
and pressure. The passivation type, pressure and power, the peel test were performed. 
They suggested that reducing the plasma pressure from 500 to 30 mTorr helped to 
improve the bond quality through the peel test for PDMS bonding. They also observed 
that silicon to PDMS bonding area through peel test increased from 0 to 80 % when the 
plasma power was fixed at 80 W and the exposure time decreased from 40 to 10 s. The 
oven treatment temperature (100 ˚C vs. 150 ˚C) did not affect the bonding quality. The 
high power effect had been tentatively attributed to the damage of the PDMS backbone at 
120 mTorr. Besides higher plasma power, an over-exposure to plasma was detrimental to 
the adhesiveness of PDMS to all the passivation materials [76, 77]. After the surface 
modification such as oxygen plasma, the channels may provide various diffusion rates in 
conjunction with the drug diffusion coefficient. 
PDMS in microfluidics, its bonding properties to other substrates including Si 
containing  and non-Si containing materials had been examined while using various 
methods such as plasma oxidization, thermal, pressure, and chemical bonding approaches 
[78]. The assorted microchannel was assembled to the PDMS reservoir and sealed using 
the O2 plasma etching processes in accordance with 600mTorr pressure and 20Wpower 
for 35 s. 
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Figure 4. 5 Device assembly process. 
The overall fabricated device was shown in Figure 4.5. The PDMS upper cover 
for the microchannel A and B were prepared by casting PDMS on a 20 by 14 cm 
rectangular Petri dish and then inspected under a microscope to identify any molding 
defects. The covers were cut into individual device and fitted with a microchannel 
substrate. Finally, the functionality of the device was being explored. 
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4.5 Experimental Procedure  
4.5.1 Contact Angle 
The contact angle was tested on the surface of PDMS and Silicon wafer with both 
water and Rhodamine B, which was used as a tracer dye to visualize the flow rate and 
direction of flow. A contact (or wetting) angle test was commonly used to assess plasma 
surface treatment.  Figure 4.6 below showed how most angles typically vary between 100 
and 110 degrees prior to treatment which were drastically reduced to around half of initial 
contact angles after processing an oxygen plasma surface treatment. 
 
Figure 4. 6 Measuring results of contact angle on the PDMS surface with water and 
Rhodamine B, and before and after oxygen plasma treatment. 
It can be seen in Figure 4.7 that the contact angle changed along the time 
increasing and the contact angle was dependant of time. The water on the PDMS 
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substrate had generally constant contact angle in relatively short time and these substrates 
for which contact angle diminished rapidly. We found that PDMS substrates without O2 
surface treatment had highest contact angle.  
 
 
Figure 4. 7 Measuring results of contact angle as a function of time on the PDMS surface 
with water and Rhodamine B, and before and after oxygen plasma treatment. 
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Figure 4. 8 Measuring results of contact angle on the Silicon surface with water and 
Rhodamine B, and before and after oxygen plasma treatment. 
 Figure 4.8 above showed that measuring results of contact angle on the silicon 
surface with water and Rhodamine B, and before and after oxygen plasma treatment. It 
could be explained that most contact angles typically varied between 78 and 83 degrees 
prior to treatment which were increased to around one thirds of initial contact angles after 
processing an oxygen plasma surface treatment 
  98 
  
Figure 4. 9 Measuring results of contact angle as a function of time on the Silicon surface 
with water and Rhodamine B, and before and after oxygen plasma treatment. 
In Figure 4.9, the contact angle decreased along the time increasing. The water on 
the silicon substrate had generally constant contact angle in relatively short time and 
these substrates for which contact angle diminished rapidly. We found that silicon 
substrates without O2 surface treatment had highest contact angle at the beginning. The 
contact angle on the silicon surface without treatment diminished much faster than no-
treatment. The O2 surface treatment could generate hydrophilic surface to obtain better 
initial flow through microchannels.  
4.5.2 Experimental Apparatus 
The main purpose of these tests was to verify the simulation results to obtain the 
optimized drug delivery device based on the desired amount of drug should be delivered 
0
20
40
60
80
100
0 10 20 30 40 50 60
Si Substrate
Si Substrate with 
Silanol
Si Substrate
Si Substrate with 
Silanol
Hydrophobicity of Silicon vs. time
Time (minute)
Co
nt
ac
t A
ng
le
 (θ
) 
Rhodamine 
Water:
  99 
for a long phase. As a first step, we needed to understand that one substance diffused in 
one direction through microchannel and how the size of microchannel and length affect 
diffusion rate. The diffusion could be generated with the relative concentration of both 
reservoirs depending on the microchannel along the time changes.  It can be seen in 
Figure 4.10 that experimental was set up of both microchannel A and B. Since the 
microchannel A had an inlet reservoir using a tube, the end of the tube which inserted 
into PDMS before curing was flattened up with sand paper. The tube was reinserted into 
the hole and glue was then quickly smeared around the tubing and hole. Epoxy glue could 
also be used to bond PDMS to tube. This allowed the creation of thick mounting blocks 
on thin PDMS providing a more durable fit.  
 
Figure 4. 10 Comparison of experimental set up between microchannel A and B. 
Single straight microchannel A was set up into a beaker (10ml volume), which 
contains DI water as an unbiased solution. The pH measurement is potentiometric that 
explains the relationship between the electrode potential and the solution. The pH meter 
truthfully responds to the potential, it indirectly and mathematically converts the potential 
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to the pH scale according to the questionable linear Nernst slope. It does not correct the 
nonlinear deviations in the strong acid and neutral regions. In general, the accuracy of pH 
measurements relied on precision calibration of pH glass electrodes, reference electrodes 
and buffers. Although it would seem that the pH meter could make an accurate 
measurement of the change of pH value with need for the calibration, the electrode had 
robustness to the pH meter to display a pH value changing pattern. A pH meter was a 
method of characterizing solution concentration by measuring pH as the activity of 
the hydrogen cations or the amount of acidity that was diffused through a device. In a 
microchannel, like a test tube of water, all of the citric acid within the drugs would be 
diffused. 
The pH/conductivity meter (Accumet® AR20, Fisher Scientific, Beverly, MA) 
with microelectrode (Ag/AgCl reference) was used to measure a rate of pH changes with 
respect to time for the entire test. The pH data were transferred and saved to computer 
through hyper network at a randomly selected time. The amount of mixed drug solution 
that contained in a reservoir was 5µℓ. DI water of 8.58 mℓ (same amount of human eye 
vitreous fluid) was used for measuring pH at a beaker. All experiments were performed 
2-3 times, each microchannel and device with essentially similar protocols, at room 
temperature (20-22°C). Single straight microchannel B was set up same as microchannel 
A except the amount of drugs and DI water. The same amount of drugs and DI water of 
0.33ml were used for both reservoirs in microchannel B.  
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Figure 4. 11 Schematic of experimental equipments and pH electrode with each 
microchannel and device. 
50 % of citric acid in a drug of eye multi- purpose solution (10g of citric acid was 
dissolved in 20ml of drug until all anhydrous crystalline was invisible) was used to 
measure the pH value which diffused through microchannel forward DI water at opposite 
site. The velocity of acid production in the outlet reservoir was calculated from the slope 
of the measured H+ activity (concentration) over time and taking into account the 
buffering capacity. 
 
4.5.3 UV-Visible Spectrophotometers 
UV-Visible Spectrophotometers was used to quantify the amount of an absorbing 
drug of the Brimonidine.  The drug solution made by dissolving 0.405g of Brimonidine 
(C11H10BrN5) in enough DI water to make 5ml of solution.  
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Test condition; 
Room temperature (~21 oC) 
UV spectrum – 248nm 
Absorbance - µV   
 
Figure 4. 12 Calibration data for the estimation of the Brimonidine, researched by 
Bhagav P et al (2010) and C.A. Holden et al (2012) [79, 80].   
 
In Figure 4.12, the graph showed that Bhagav P et al [79] estimated the 
calibration data for concentration of the Brimonidine while measuring the absorbance of 
UV-Vis. at 248nm. It was depicted that the increasing drug concentration was linearly 
proportional to the absorbance. These estimations were implemented into our experiment 
results after obtained observance (Y= µV) while using the UV-Visible 
Spectrophotometers.  
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4.5.4 Diffusion Test with Microchannel A 
Like for all potentiometric methods, the output signal was linear with the 
logarithm of concentration, i.e. at two different pH values the same change in pH value 
corresponds to different changes in concentration. To convert slopes of pH to metabolic 
fluxes of acidification, the pH values must therefore be converted to actual 
concentrations. We found an equilibrium concentration when drug solution was fully 
diffused out through all volume. It can be seen in Figure 4.13 that normalized pH values 
were continuously reduced to equilibrium concentration with respect to time. We were 
not quite sure that 250 µm microchannel performed somewhat differently compare to 
others. However we assumed that a leakage occurred at the gluing interface while 
measuring pH acidity. Experimental data of microchannel A for cumulative drug release 
versus time was shown in Figure 4.14. 
 
Figure 4. 13 Experimental data of microchannel A for normalized pH value versus time, 
pHi is pH value at each time increase, pH0 is pH value at the initial condition. 
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Figure 4. 14 Experimental data of microchannel A for cumulative drug release versus 
time. 
4.5.5 Diffusion Test with Microchannel B 
The rest of the measuring parameter and converting pH value to normalized 
number were identical with microchannel A. We also found an equilibrium concentration 
when drug solution was fully diffused out through all volume for experimental 
microchannel B. It can be seen in Figure 4.15 that normalized pH values were 
continuously reduced to equilibrium concentration with respect to time. The entire 
microchannel performed well as we expected that diffusion occurred dependently with 
microchannel size and concentration gradients. Experimental data of microchannel B for 
cumulative drug release versus time was shown in Figure 4.16. 
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Figure 4. 15 Experimental data of microchannel B for normalized pH value versus time, 
pHi is pH value at each time increase, pH0 is pH value at the initial condition. 
 
Figure 4. 16 Experimental data of microchannel B for cumulative drug release versus 
time. 
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4.5.6 Diffusion Test with Entire Device  
The experimental data of entire device was shown in Figure 4.17. As we 
expected, the normalized diffusion data was in identical directions. Also noted that at the 
extreme end of each curves was not exceeded the calibrated pH scale and equilibrium 
concentration after 10 days. The obtained pH data were normalized by dividing each data 
point by the initial value for each test of microchannel. We generated a graph the 
normalized data versus time for each measurement and then fitted a logarithmic trend line 
to each curve. 
 
 
 
Figure 4. 17 Experimental data of entire device for normalized pH value versus time, pHi 
is pH value at each time increase, pH0 is pH value at the initial condition. 
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Figure 4. 18 Experimental data of entire device for cumulative drug release versus time. 
 
4.5.7 Micro-Particle Image Velocimetry (µPIV) 
The combination of Matlab  µPIV functions and images were a powerful 
instrument for exploring other dynamic aspects of diffusion. A typical problem was to 
find out the rate of influx of particles to a certain fraction of objective space and in many 
interesting instances. For instance, how long it would take a particle that started at some 
position to reach some region. Since diffusion was not a deterministic process, the result 
would be a distribution of travel times for a given set of identical particles all following 
the same boundary and initial conditions. In some instances that distribution was 
agreeable to calculating a mean rate or median rate of arrival. In Figure 4.19, the images 
were obtained the diffusion of particles at the inlet microchannel at each time step. The 
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following a defining specific region and vector plot under calibration of actual distance 
were very important process to achieve constant evaluations. 
 
Figure 4. 19 Data mining process after obtaining images at each times using PIV methods 
in MATLAB. 
 
The results of velocity magnitude of microchannel were shown in Figure 4.20. 
Images were captured at different time steps for each microchannel. Due to high mass 
density of polystyrene particles (3µm diameter), the velocity magnitude of the particles 
are relatively slow in comparison with citric acids. The difference of the velocity 
magnitude among the cross section of microchannel was not significant after diffusing for 
5 minutes.   
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Figure 4. 20 Results of velocity magnitude of microchannel B, images were captured at 
different time steps for each microchannel. 
 
We considered a one-dimensional particle which diffuses freely in the presence of 
a microchannel at x = 0. The diffusion equation could be solved with initial condition and 
boundary condition at x = l. Assumed that the microchannel, i.e., which transferred every 
particle diffusing on it, was located at x = 0, this situation was governed by the Einstein 
diffusion equation in one dimension. 
∂c(x; t|x0, t0) / ∂t = D ∂2c(x; t|x0, t0) /∂x2      (32) 
Once we converted the actual concentration c to the normalized concentration M with a 
percentage of particles in liquid volume, the normalized particle flux can be expressed by 
[81] 
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(33) 
Although there were some variations between each microchannel, the result of velocity 
magnitude of microchannel B was apparently agreed with an analytical solution of 
500µm channel in Figure 4.21.  
 
Figure 4. 21 Results of velocity magnitude of microchannel B with an analytical solution 
of 500µm channel. 
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4.6 Comparison of Simulation and Tests 
4.6.1 Microchannel A and B 
For each microchannel as function of time shown in Figure 4.13 and 4.15, 
diffusion constant was derived by fitting the error function to the measurement values. 
For the shortest diffusion time of 30 min a diffusion constant of D = 1.42 x 10-7 m2/s was 
obtained. For the longer diffusion times an average diffusion constant was much less than 
initial diffusion constant. However, the experimental values of 250µm channel were so 
fast that did not fit of the theoretical curve. This fact suggested that device itself may 
have any critical leakage problems as shown in Figure 4.22.  As these data points were 
not considered to be calibrated, they would be discarded. 
 
Figure 4. 22 Comparison of normalized value of microchannel A between simulation and 
tests. 
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Finally noted that there were positions where the motion of the diffusion 
performed rapidly. We assumed another reason that this was due to temperature drops in 
the laboratory during the night and had little impact on the analysis of the data.   
 
Figure 4. 23 Comparison of normalized value of microchannel B between simulation and 
tests. 
For device samples with different geometry microchannels, the effective diffusion 
coefficient which minimized differences between simulation and experimental values 
was agreed. The diffusion coefficient value was verified performing another experiment. 
As a realistic solution for the diffusion coefficient, an error function was considered to 
generate the nonlinear logarithmic curves as function of time. This equation including 
error function was the solution in the case of a constant source of concentration with the 
diffusion coefficient and the time. The boundary condition of a constant source was not 
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fully satisfied in our experiment as can be seen in Figure 4.23 since the concentration in 
the reservoir decreased over time. 
4.6.2 Entire Device 
 
Figure 4. 24 Comparison of normalized value of entire device between simulation and 
tests. 
The simulation showed agreement with the experiments. It can be seen in Figure 
4.24 that after 8 days, each type of micrchannel geometry generated a different diffusion 
rate. The diffusion rate of tournament microchannel was bit higher than the others.   
 
 
4.6.3 Simulation Results of Drug Release between Microchannel A and B 
In the graph (Figure 4.24), drug release rate as a function of time for the 
microchannel A and B was calculated using a diffusion coefficient and error function 
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method. Our graph exhibited the same trend line as that obtained in the simulation results. 
This graph ignored the effects of peak value at the small cross section of microchannel.  
The coefficient of this logarithmic curve was well fitted with those that simulations were 
done.  
 
Figure 4. 25 Comparison of simulation results of drug release time between microchannel 
A and B. 
   
It can be denoted that the range of 0.02~0.05 mm2 may satisfy the drug release for 
12 - 36 months. It can be predicted that the microchannel size of square of 210.8, 173.4, 
and 142.8 µm may satisfy the drug delivery term such as 12, 24, and 36 months, 
respectively (Table 5). 
 
Table 5 Optimized Microchannel size based on simulation results. 
Drug Release Time 
12 months 24 months 36 months 
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Square channel 210.8 x 210.8µm 173.4x 173.4µm 142.8 x 142.8µm 
Rectangular channel 200 x 222.2 µm 200 x 150.5 µm 200 x 102.0 µm 
 
Table 4.1 values were used in an attempt to model diffusion and consequently calculated 
the effective diffusion coefficient and release rate in period of month. 
 
4.6.4 Experimental Results of Drug release between Microchannel A and B 
Drug release rate as a function of time for the microchannel A and B was 
calculated in the graph (Figure 4.25) using a measured pH value that converted to 
normalized value. Our graph exhibited the same trend line as that obtained in the 
experimental results. This graph also ignored the effects of peak value at the small cross 
section of microchannel.      
 
 
Figure 4. 26 Comparison of experimental results of drug release time between 
microchannel A and B. 
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Although the drug release rate of microchannel size between 0.03 and 0.05 µm 
were not expectable, it can be denoted that the range of 0.02~0.05 mm2 may satisfy the 
drug release for 12 - 36 months. It also can be predicted that the microchannel size of 
square of 192.3, 174.1, and 162.3 µm may satisfy the drug delivery term such as 12, 24, 
and 36 months, respectively (Table 6). 
 
Table 6 Optimized Microchannel size based on experimental results. 
Drug Release 
12 months 24 months 36 months 
Square channel 192.3 x 192.3µm 174.1 x 174.1µm 162.32 x 162.32 µm
Rectangular channel 
200 x 185 µm 200 x 151.5 µm 200 x 131.7 µm 
250 x 148µm 250 x 121.2µm 250 x 105.4 µm 
500 x 74µm 500 x 60.6µm 500 x 52.7 µm 
 
4.6.5 t test Two Sample Assuming Equal Variances 
We performed the t-test, which assumes that the two samples had equal ariances. For 
simple evaluation, the average difference between the simulation and tests were 7.6%, which 
was little higher than we expected, however it may have acceptable range for this 
investigation.   
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Table 7 Comparison of microchannel size between simulation and experimental results. 
Drug release 
12 months 24 months 36 months 
Microchannel 
(square of) 
Simulation 210.8 µm 173.4 µm 142.8 µm 
Experiment 192.3 µm 174.1 µm 162.3 µm 
% of difference 8.78% 0.40% 13.67% 
Average 7.62% 
Since the t statistic of -0.026 in one-tail was smaller than the critical value of 2.13 and 
probability of 0.98 in two-tail also was smaller than the critical value of 2.77; failed to 
reject the null hypothesis.  The null hypothesis was that these means of simulation and 
experiment were equal (Significance level p>0.05).  
   
Table 8 t test Two Sample Assuming Equal Variances. 
Mean Variance t Stat 
P(T<=t) 
one-tail 
t Critical 
one-tail 
P(T<=t) 
two-tail 
t Critical 
two-tail 
Simulation 175.667 1159.85 -0.0263 0.49012 2.13185 0.98025 2.77645 
Experiment 176.233 228.413 
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4.6.6 Diffusion Results of the Bimonidine 
 
Figure 4. 27 Comparison of simulation (COMSOL) and experiments (UV-Vis) with 
microchannel A 
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Figure 4. 28 Comparison of simulation (COMSOL) and experiments (UV-Vis) with 
device 
In Figure 4.27, results showed that after 24 hours, Brimonidine (C11H10BrN5), 
with a molecular weight of 292 g/mole, obtained the biggest section of microchannel 
obtained the faster diffusion rate than the other small sections. Y-axis is a normalized 
data, which derived from an observance at 248nm (1- µVi / µVpeak) with respect to time.  
The simulation showed agreement with the experiments. It can be seen in Figure 
4.48 that after 4 days, each type of microchannel geometry generated a different diffusion 
rate. The diffusion rate of tournament microchannel was bit higher than the others, which 
was similar to result with citric acid experiments.   
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Table 9 Drug concentration after 24 hours was determined by the regression equation  
Amount of 
drug  
Microchannel A  
100 µm  250 µm  500 µm  750 µm  1000 µm  
Concentration 
(µg/ml) / day 0.6455 0.7883 1.037 1.4338 1.6031 
  
Microchannel 
Straight  Meshed  Tournament  Osmotic  
Absorbance 
(µV)  0.404 0.446 0.494 0.369 
Concentration 
(µg/ml) / day  6.3333 7 7.7619 5.7778 
Drug Release  
(0.59mg/ml)  93 days 84 days 76 days  102 days  
 
Based on the research papers written by  Bhagav P et al [79] and C.A. Holden et 
al [80], the regression equation, C = (Y (absorbance) – 0.005)/0.063 could be used to 
estimate the drug concentration after 24 hours diffusion.  In this experiment, the diffusion 
rate of the Brimonidine was approximately 16% faster than Citric acids that diffused 
through a 100µm channel after 24 hours. The drug release with 0.59mg/ml drugs could 
diffuse freely through a microchannel for over 102 days with a device including an 
osmotic channel as shown in table 9. 
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4.7 Discussion  
The top and bottom covers were fabricated from PDMS through replica-molding 
techniques. The microchannels along with top and bottom covers were all integrated into 
the device. The experiment was designed to maintain a constant distance between the 
drug delivery device and the electrode, which was preferable for two reasons. First, by 
maintaining a constant distance from the outlet of the drug delivery device, the diffusion 
of the citric acid needed not to be adjusted to the output of the pH measurement. As long 
as the electrode distance remained constant, the output of the pH meter was all that was 
needed to determine the size of the microchannels.  
The microchannel and device were being tested for its functionality and diffusion 
characteristics. However, there were significant challenges related to achieving reliable 
and sustainable micro scale geometry on a silicon, bonding, diffusion of the drug into 
channels, and controllability. The test evaluation was performed measuring the change in 
pH of a neutral solution using a strong citric acid; it could be diffused out through the 
device. The final pH test of the theoretical calculations was to apply the nonlinear 
logarithmic curve to correct a set of measurements and compare them to a reference 
measurement. The form of the nonlinear residue curves was quite comparable, showing 
the same nonlinear trends and the increase in nonlinearity as the area of microchannel 
was decreased. In terms of absolute value, a comparison of these showed those in all 
cases the theoretical curves were actually slightly larger than the experimental curves. It 
was hypothesized that one possible reason for this inconsistency may be the presence of 
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additional factors in the entire device that leak small amounts of acid to the outlet and 
place the distance of the measuring probe. It is well known that indeed the diffusion rate 
between the Brimonidine and Citric acid were significantly different because the lighter 
the particle was going to move the faster. 
 The simulations showed different behavior for thermal and for mass, which was 
due to the different values of the Lewis number, diffusivity. The heat and mass transport 
were both diffusion dominated and the differences were determined by the highly 
unequal diffusivities. The presence of an additional factors term may raise the magnitude 
of the velocity, but further work would be required to prove this.  Since the t statistic for 
both simulation and experiment was smaller than the critical value, these two variables 
were equal. The drug release rate with specific size of microchannel was satisfied to 
diffuse for 1-3 years. These challenges were being addressed and were presented. 
 
4.8 Summary  
This chapter described an experimentally verified diffusion scheme between a 
PDMS reservoir and various size of microchannel. A PDMS reservoir was chosen 
because of its biocompatible and typically no reaction with drug substance. The entire 
drug delivery system except silicon microchannel could therefore be modeled completely 
in the simple structure.  To quantify the release of the drug molecules from the reservoir 
we used pH meter. The value of pH meter observed could be correlated to the 
concentration of the drug. 
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As results of microchannel diffusion measurement in light intensity, we could 
clearly understand that the distance from the inlet reservoir to microchannel or 
microchannel to outlet reservoir was significantly effects for the diffuion rate as a 
function of time. When the pH probe on the right was positioned above a device, the 
resulting data revealed the differences between the outlet measurement and the vertical 
measurement. We could consider this outlet measurement as the actual distance. 
Comparing the diffusion rate between the end of microchannel and middle of outlet 
reservoir were consequently different as shown in Figure 4.29. Therefore keeping the 
consistent measuring position was one of the important procedures to obtain reliable data. 
 
 
Figure 4. 29 Results of microchannel diffusion with a width of 1000µm and a height of 
500 µm, Light intensity measurements modified from Heeren A. et al [72]. 
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 The main reason for maintaining a constant distance had been illustrated in 
Figure 4.29. Specifically, for different microchannel size of both the nominal distance 
and the increase were affected. By positioning the exact fixture at the nominal distance, 
the variation factor was removed from consideration. 
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CHAPTER 5 Conclusions and Recommendations 
5.1 Conclusions  
Microchannels were significant components of miniaturized passive diffusion 
fluid systems. They were used for example to direct the diffusion flow from inlet to outlet 
in miniaturized PDMS device. 
Variations of drug diffusion rate of all models from single microchannel to entire 
device were carried out through simulations and experiments. The analytical simulations 
and experiments for microchannels and device were conducted to verify the diffusion rate. 
Based on the proposed single channel dimension, the geometry and size of channels 
could be modified to satisfy the specification of diffusion rates for ocular drug delivery 
device. Moreover a surface of device should be manipulated in order to keep an 
optimized implant angle and to avoid a patient’s inconvenience. Various approaches had 
been tested experimentally to increase the efficiency of ocular drug delivery device. 
These drug delivery devices were designed to provide relatively constant drug delivery 
over long periods of time, making it easier for patients to remain adherent to treatment 
and possibly reducing the risk of side effects. 
 
5.1.1 Hydrophobic to Hydrophilic  
Obtaining a good seal between microchannel substrate and PDMS reservoir was 
important in preventing leakage after the drugs were filled. The plasma treated PDMS 
and microchannels provided a more reliable seal than any other bonding methods for 
microchannel. Moreover, the surface of PDMS and microchannel showed that the 
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hydrophobicity switched to hydrophilic after processing oxygen plasma that both PDMS 
and microchannel were ready to make a free diffusion easy. 
 
 
5.1.2 Comparison of Simulation and Test   
 
The diffusion characteristic of a microchannel was the result of two effects. First, 
the diffusion coefficient of the drug in a solution led to a concentration dependent gap. If 
the shape of the gap was known, the microscopic flow through the gap could be 
calculated. From the theoretical point of view this can be done either by finite-element 
analysis or by approximate formulae. From the experimental point of view, the diffusion 
characteristic of microchannel could be recorded by pH and UV-Vis measurements. 
Typical diffusion characteristic curves of passive microchannel, made by 
microfabrication of silicon, were depicted in Figure 4.2. In many cases a very non-linear 
behavior can be seen in forward direction. So it was impossible to define a constant 
diffusion flow coefficient.  
Variations of drug diffusion rate of all models from single microchannel to entire 
device were carried out through simulations and experiments. The analytical simulations 
and experiments for microchannels and device were conducted to verify the diffusion rate. 
A thorough analysis of both the simulation and experimental data had shown the 
importance of diffusion coefficient whenever the microchannel was applied to a medium. 
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Otherwise the accuracy of the experimental data, in terms of absolute distance, linearity, 
and consistency, was called into question.   
Use of the values of the diffusion coefficients and normalized constant obtained 
from our device measurements, both lower than those used by simulation of 
microchannel A and B, and entire device implantation in eye. It still led to the prediction 
of substantial effects. These should affect the reduced coefficient in the way predicted in 
the simulation. The results were consistent with the prediction, suggesting a 
microchannel sensitive to the present device. 
Eventually it may be possible to develop a set of general, nondimensionalized 
equations or curves that represented the changes in slope as a function of diffusion 
coefficient with microchannels. Practical measurements such as an experiment of a 
particular microfluidic device can be used as a guide for selection of microchannel 
geometry and cross section. For comparison with the results of microchannel A and B, 
measurements were made in the pH meter a citric acid concentration of 0.5 g/ml. The 
results were converted to normalized value which initial pH value was divided by 
measured pH value at each time for hundred hours and plotted in Figure 4-12, 4-13. It 
was clear that there was a marked effect of citric acid concentration with size of 
microchannel. It appeared to be significant deviations occurring from nonlinearity of 
diffusion against size of microchannel.  
Some factors may have affected the rate of diffusion of the substances in the 
experiment which may have led to inaccurate results. Such factors may include but were 
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not limited to inconsistent temperatures and concentrations, the type of medium used, or 
handling and execution of the experiment. 
 
5.1.3 Drug Delivery Device Models  
Based on the proposed single channel dimension, the geometry and size of 
channels can be modified to satisfy the requirement of diffusion rate for ocular drug 
delivery device. Since all these experimental results exhibited non-linearity, this fact 
would tend to make the variations seen in Figure 4-15, which was greater or less than 
they would be if assumed at constant velocity gradient. However, it can be assumed that 
the measuring position of ph electrode in a beaker made variations as we had known from 
research paper by Heeren et al [70]. 
   
5.1.4 Determination of Drug Release Time 
The results of test represent the straight single channel of square 192, 174, and 
162 µm can get diffusion rates that release drugs for over 1, 2, and 3 years respectively. 
Although the simulation results of drug release rate were around 7% different, the rate of 
microchannel size was fairly agreed with the experimental results.   
A variation against the simulation results, our experiment showed some sort of 
inconsistency with our early mentioned hypothesis on the first experiment of 
microchannel A. The rate of diffusion of a substance was affected by its molecular 
weight. As the molecular weight increased, the rate of diffusion was generally low. This 
  129 
was because the larger the size of a particle, a greater amount of force, in this case, 
thermal energy was required to move the particle [84].   
 
5.2 Scientific Contributions  
Although these results showed a complex relationship of diffusivity to size of 
microchannel, concentration changes and diffusion rate, two interesting conclusions 
could be drawn from them; (i) The diffusivity was strongly dependent on size of 
microchannel under all conditions. (ii) There was a remarkable dependence of 
microchannel geometry on diffusion coefficient with relatively high concentration at the 
inlet. 
This study provided beneficial results to determine the diffusivity of drugs or any 
other micro/nano particles flow through the microchannel. We developed a novel channel 
design and further simulate, optimize, fabricate, and test to obtain the state of art drug 
delivery devices. The present device could be applicable other applications with the 
multi-scale model, e.g., drug delivery for targeted tissues and cancer disease.  
The detailed drug diffusion description in this model allowed for the investigation 
of many design parameters relevant to biomedical engineering. This case presented the 
effect of microchannel on drug release as a function of time and geometry. Furthermore, 
it was straightforward to study the influence of the drug similarity by varying the rate 
constants, or the influence of drug loading by varying the drug density. The ability to 
examine alternative microchannel geometries and simple membrane structure of PDMS 
could give even more design flexibility. 
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5.3 Recommendations  
Therapeutic drug levels could be achieved in the vitreous body of eye with a 
smaller implanted device dose if the molecular size of the drug was reduced. The smaller 
device decreased the systemic drug load however possibly reduced the incidence of 
serious systemic side effects [84, 85]. 
Since microchannels provided a nonlinear diffusion rate after the drugs reach the 
outlet of device, a careful operation was necessary to fully fill out drugs into the 
microchannels. Various geometries of microchannel may prevent a back diffusion flow of 
drugs from the vitreous humor. The drug reservoir should be considered to be a semi-
sphere or cylindrical to minimize the residual drugs while operating for a long period of 
time as shown in Figure 5.1.  
 
 
Figure 5. 1 Schematic of new design concept with sphere dome reservoir for reducing 
residual drugs. 
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Figure 5. 2 Contour plot of molecular flow rate with new microchannel. 
 
5.4 Future Works 
Although large variability was common in ocular pharmacokinetic studies, an 
additional cause of variability in the present studies may effect that the drugs were 
administered as diffusion from the implanted device that did not immediately dissolve 
within the vitreous cavity. To ensure as small as possible the residuals drugs remained in 
the device, new design concept model was necessary and to be optimized.  
Developing around less than100 µm of microchannels on a PDMS substrate may 
be a big challenge to make a biocompatible and biodegradable device. Hydrogels could 
stimulate the fluid flow as a pressure driven resource while shrinking or swelling with pH 
response. A hydrogels-based microvalve could be another way to control the drug release.  
Having an array of orifices or mesh-like holes with an internal structure designed to 
anchor the hydrogels while allowing it to gate the flow across the membrane. The 
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hydrogels could completely occupy the empty space of the orifice, completely blocking 
pressure-driven fluid flow [73].   
 
Figure 5. 3 Experiment of 200µm microchannel flow with pH responsive hydrogels (pH 
4 to 8) while swelling. 
 
An electrochemically actuated bilayer diaphragm as a low cost and low power 
micropump concept that was composed of a PDMS membrane was investigated by Kim 
[86]. In Figure 5.4, an isometric view and structure of concept design is illustrated, which 
is similar to piezo- actuation mechanisms. New micropump models were considered to 
optimize micro-flow efficiency and filtering micro-particles. These micropump models 
consisted of microchannels, connecting one pump chamber and an inlet/outlet ports and 
piezo-actuator on the top of chamber operated by a two-phase input power. All 
components except the piezo-actuator were fabricated with PDMS elastomer. The 
diameter and thickness of the actuator diaphragm were 5mm and 500µm, respectively. 
 
Hydrogels 
Microchannel 
Reservoir Reservoir 
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Figure 5. 4 Schematic of new micropump for experimental application. 
 
The length, width and the depth of the microchannel were 250, 100 and 50µm, 
respectively. If the two-phase electrical power is applied to the piezo-actuator, the 
pressure in the sealed actuator chamber was varied by the size of microchannel and total 
movement of membrane in the actuator chamber. The magnitude of the electric power 
could be determined by the pressure change amount. If the two-phase input power signal 
was applied to the piezo-actuator of the micropump, the two-phase motions of the 
actuator diaphragms conveyed the fluid in the pump chamber. We assumed that the 
working fluid should be sucked into the inlet chamber and pushed out from outlet 
chamber. Based on these fluid release kinetics and transport mechanisms of 
biodegradable polymeric actuation system, it could be considered in the future works.  
The schematic of a check valve integrated into microfluidic drug delivery devices 
was shown in Figure 5.5. The polystyrene ball can be acted as a value to close or open the 
fluid flow while maintaining consistent diffusion flow. The coupled structure simulation 
is required to predict the behavior of the check valve for further discussion. 
 
 
Piezoelectric 
actuator 
Microchannel 
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Figure 5. 5 Schematic of a check valve integrated into microfluidic drug delivery devices  
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